View Filing Data

Print Document View Excel Document

Document and Entity Information Document - USD ($)	12 Months Ended
Document and Entity Information Document - USD ($)	Dec. 31, 2013	Mar. 11, 2014	Jun. 30, 2013	Dec. 31, 2012	Nov. 19, 2010
Document Information [Line Items]
Entity Registrant Name	NeoStem, Inc.
Entity Central Index Key	0000320017
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Document Type	10-K
Document Period End Date	Dec. 31, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		28,582,625
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Public Float			$ 92,272,275
Sale of Stock, Price Per Share			$ 5.60		$ 0.945
percent of outstanding common stock			10.00%
Common Stock, Par Value	$ 0.001	$ 0.001		$ 0.001

Consolidated Balance Sheets - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Current Assets
Cash and cash equivalents	$ 46,133,759	$ 13,737,452
Accounts receivable trade, net of allowance for doubtful accounts of $391,829 and $626,054, respectively	1,860,835	1,053,604
Inventory	1,270,223	1,113,025
Prepaids and other current assets	1,561,933	803,135
Total current assets	50,826,750	16,707,216
Property, plant and equipment, net	12,844,216	11,153,143
Goodwill	11,117,770	11,117,770
Intangible assets, net	13,875,617	14,480,827
Other assets	1,151,729	947,307
Assets, Total	89,816,082	54,406,263
Current Liabilities
Accounts payable	3,354,908	2,555,240
Accrued liabilities	4,018,026	2,284,813
Notes payable	381,097	202,558
Mortgages payable	213,112	3,438,475
Derivative Liabilities, Current	23,175	0
Unearned revenues	1,816,601	1,468,341
Total current liabilities	9,806,919	9,949,427
Deferred income taxes	4,379,226	3,599,122
Notes payable	531,164	171,528
Long-term Debt	3,023,609	0
Derivative liabilities	0	101,156
Acquisition-related contingent consideration	9,450,000	7,550,000
Other long-term liabilities	598,729	214,871
Total liabilities	27,789,647	21,586,104
Commitments and Contingencies
Stockholders' Equity
Preferred stock; authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at December 31, 2013 and December 31, 2012	100	100
common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 27,196,537 and 16,375,365 shares, at December 31, 2013 and December 31, 2012, respectively	27,197	16,375
Additional paid-in capital	299,594,525	231,218,615
Treasury stock, at cost	(705,742)	(665,600)
Accumulated deficit	(236,373,605)	(197,392,361)
Total NeoStem, Inc. stockholders' equity	62,542,475	33,177,129
Noncontrolling interests	(516,040)	(356,970)
Total equity	62,026,435	32,820,159
Liabilities and Equity, Total	$ 89,816,082	$ 54,406,263

Consolidated Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Accounts receivable trade, net of allowance for doubtful accounts	$ 391,829	$ 626,054
Convertible Redeemable Series E Preferred Stock, shares designated	0	0
Convertible Redeemable Series E Preferred Stock, liquidation value per share	$ 0.00	$ 0.00
Convertible Redeemable Series E Preferred Stock, issued	0	0
Convertible Redeemable Series E Preferred Stock, outstanding	3,135,411	6,662,748
Preferred Stock, authorized	20,000,000	20,000,000
Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, par value	1	1
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares designated	825,000	825,000
Preferred stock, issued	10,000	10,000
Preferred Stock, Shares Outstanding	10,000	10,000
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares, Issued	27,196,537	16,375,365
Common Stock, Shares, Outstanding	27,196,537	16,375,365

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Revenues	$ 14,668,455	$ 14,329,889
Cost of revenues	12,947,217	11,949,124
Gross profit	1,721,238	2,380,765
Research and development	16,917,396	10,451,070
Selling, general, and administrative	21,612,793	22,315,346
Operating Expenses	38,530,189	32,766,416
Operating loss	(36,808,951)	(30,385,651)
Other income (expense):
Other (expense) income, net	(1,614,858)	(4,314,228)
Interest expense	(281,421)	(1,576,975)
Nonoperating Income (Expense), Total	(1,896,279)	(5,891,203)
Loss from operations before provision for income taxes and noncontrolling interests	(38,705,230)	(36,276,854)
Provision (benefit) for income taxes	780,104	(175,533)
Net loss from continuing operations	(39,485,334)	(36,101,321)
Loss from discontinued operations - net	0	(30,267,990)
Net loss	(39,485,334)	(66,369,311)
Less - loss from continuing operations attributable to noncontrolling interests	(504,090)	(287,181)
Less - loss from discontinued operations attributable to noncontrolling interests	0	(12,312,646)
Net loss attributable to NeoStem, Inc.	(38,981,244)	(53,769,484)
Warrant inducements	0	(1,012,819)
Preferred dividends		(528,023)
Amounts Attributable to NeoStem, Inc. common shareholders:
Loss from continuing operations	(38,981,244)	(35,814,140)
Loss from discontinued operations - net of taxes	0	(17,955,344)
Warrant inducements	0	(1,012,819)
Preferred dividends	0	(528,023)
Net loss attributable to NeoStem, Inc. common stockholders	$ (38,981,244)	$ (55,310,326)
Basic and diluted (loss) per share attributable to:
Continuing operations	$ (1.90)	$ (2.59)
Discontinued operations	0.00	(1.30)
NeoStem, Inc. common stockholders	$ (1.90)	$ (4.00)
Weighted average common shares outstanding	20,495,771	13,841,997

Consolidated Statements of Comprehensive income - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Net loss	$ (39,485,334)	$ (66,369,311)
Other comprehensive income (loss):
Foreign currency translation elimination on exit of segment	0	(169,993)
Foreign currency translation elimination on sale of segment	0	(4,387,371)
Foreign currency translation	0	405,021
Total other comprehensive (loss) income	0	(4,152,343)
Comprehensive loss	(39,485,334)	(70,521,654)
Noncontrolling interests elimination on sale of segment	0	(6,014,981)
Comprehensive loss attributable to noncontrolling interests	(504,090)	(12,448,950)
Comprehensive net loss attributable to NeoStem, Inc. common stockholders	$ (38,981,244)	$ (52,057,723)

Consolidated Statements of Equity - USD ($)	Total	Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Total NeoStem, Inc. Shareholders' Equity [Member]	Non-Controlling Interest in Subsidiary [Member]
Beginning Balance (in shares) at Dec. 31, 2011		10,000	10,932,959
Beginning Balance at Dec. 31, 2011	$ 80,132,518	$ 100	$ 10,933	$ 200,957,035	$ 4,152,343	$ (143,094,854)	$ 0	$ 62,025,557	$ 18,106,961
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(66,369,311)					(53,769,484)		(53,769,484)	(12,599,827)
Foreign currency translation	385,905				235,028			235,028	150,877
Share-based compensation (in shares)			336,427
Share-based compensation	6,712,536		$ 336	6,712,200				6,712,536
Proceeds from issuance of common stock (in shares)			3,573,229
Proceeds from issuance of common stock	16,428,827		$ 3,573	16,425,254				16,428,827
Net proceeds from exercise of options	0
Proceeds from warrant exercises (in shares)			1,107,618
Proceeds from warrant exercises	6,604,419		$ 1,108	6,603,311				6,604,419
Shares, options and warrants received in Erye Sale	(1,117,901)			(452,301)			(665,600)	(1,117,901)
Elimination of Equity upon Erye Sale	(10,402,352)			0	(4,387,371)			(4,387,371)	(6,014,981)
Repayment of Series E Preferred Principal and Dividends (in shares)			279,238
Repayment of Series E Preferred Principal and Dividends	$ 674,194		$ 279	1,201,938		528,023		674,194
Warrant inducements	41,969		145,895
Warrant inducements	$ (228,676)		$ (146)	(228,822)				(228,676)
Ending Balance (in shares) at Dec. 31, 2012		10,000	16,375,365
Ending Balance at Dec. 31, 2012	32,820,159	$ 100	$ 16,375	231,218,615	0	(197,392,361)	(665,600)	33,177,129	(356,970)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(39,485,334)					(38,981,244)		(38,981,244)	(504,090)
Share-based compensation (in shares)			513,912
Share-based compensation	6,838,559		$ 514	6,878,187			40,142	6,838,559
Proceeds from issuance of common stock (in shares)			9,712,724
Proceeds from issuance of common stock	58,736,166		$ 9,713	58,726,453				58,736,166
Proceeds from option exercises, shares			31,369
Net proceeds from exercise of options	150,658		$ 31	150,627				150,658
Proceeds from warrant exercises (in shares)			563,167
Proceeds from warrant exercises	$ 3,028,241		$ 564	3,027,677				3,028,241
Warrant inducements	40,407		0
Warrant inducements	$ (62,014)		$ 0	(62,014)				(62,014)
Change in Ownership in Subsidiary				(345,020)				(345,020)	345,020
Ending Balance (in shares) at Dec. 31, 2013		10,000	27,196,537
Ending Balance at Dec. 31, 2013	$ 62,026,435		$ 27,197	$ 299,594,525	$ 0	$ (236,373,605)	$ (705,742)	$ 62,542,475	$ (516,040)

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net loss	$ (39,485,334)	$ (66,369,311)
Loss from discontinued operations	0	30,267,990
Adjustments to reconcile net loss to net cash used in operating activities:
Common stock, stock options and warrants issued as payment for compensation, services rendered and interest expense	6,838,559	6,712,536
Depreciation and amortization	1,605,608	1,550,571
Amortization of preferred stock discount and issuance cost	0	1,609,495
Changes in fair value of derivative liability	(77,981)	(373,307)
Changes in acquisition-related contingent consideration	1,900,000	4,420,000
Loss on disposal of assets	0	13,653
Bad debt (recovery) expense	(234,225)	511,755
Deferred income taxes	780,104	(175,533)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(758,798)	(178,011)
Accounts receivable	(573,005)	(554,884)
Inventory	(157,198)	(465,280)
Unearned revenues	348,260	178,008
Other assets	(204,422)	2,414,842
Accounts payable, accrued expenses and other liabilities	2,916,739	1,677,551
Net cash used in operating activities - continuing operations	(27,101,693)	(18,759,925)
Net cash provided by operating activities - discontinued operations	0	4,907,407
Net cash used in operating activities	(27,101,693)	(13,852,518)
Cash flows from investing activities:
Cash received in divestiture	0	12,280,000
Acquisition of property and equipment	(2,691,471)	(531,315)
Net cash provided by (used in) investing activities - continuing operations	(2,691,471)	11,748,685
Net cash used in investing activities - discontinued operations	0	(5,660,305)
Net cash provided by (used in) investing activities	(2,691,471)	6,088,380
Cash flows from financing activities:
Net proceeds from exercise of options	150,658	0
Net proceeds from exercise of warrants	3,028,241	6,604,418
Net proceeds from issuance of capital stock	58,736,165	16,428,827
Repayment of mortgage loan	(201,754)	(196,585)
Proceeds from notes payable	1,041,347	666,501
Repayment of notes payable	(503,172)	(440,477)
Repayment of preferred stock	0	(5,394,263)
Payment of dividend for preferred stock	0	(327,748)
Payment for warrant inducement	(62,014)	(228,676)
Net cash provided by financing activities - continuing operations	62,189,471	17,111,997
Net cash used in provided by financing activities - discontinued operations	0	(8,370,228)
Net cash provided by financing activities	62,189,471	8,741,769
Impact of changes of foreign exchange rates	0	14,389
Net increase in cash and cash equivalents	32,396,307	992,020
Cash and cash equivalents at beginning of period	13,737,452	12,745,432
Cash and cash equivalents at end of period	46,133,759	13,737,452
Cash paid during the period for:
Interest	274,100	1,771,800
Taxes	0	2,100,000
Supplemental Schedule of non-cash investing activities:
Capitalized interest	0	182,000
Common stock, warrants and options received upon sale of Erye	0	1,117,901
Supplemental schedule of non-cash financing activities
Common stock issued pursuant to the redemption of Convertible Redeemable Series E 7% Preferred Stock	0	1,026,600
Common stock issued in payment of dividends for the Convertible Redeemable Series E 7% Preferred Stock	$ 0	$ 175,700

The Business

12 Months Ended

Dec. 31, 2013

The Business [Abstract]

Nature of Operations [Text Block]

The Business

Overview

NeoStem, Inc. (“we,” “NeoStem” or the “Company”) is a leader in the emerging cellular therapy industry. We are pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that cell therapy will play a large role in changing the natural history of diseases as more breakthrough therapies are developed, ultimately lessening the overall burden of disease on patients and their families as well as the economic burden that these diseases impose upon modern society.

Our business includes the development of novel proprietary cell therapy products as well as a revenue generating contract development and manufacturing service business that we not only leverage for the development of our therapeutics but anticipate will benefit from the advancement in the regenerative medicine industry. The combination of our own therapeutic development business and a revenue-generating service provider business provides the Company with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

We are developing therapies to address ischemia through our CD34 Cell Program. Ischemia occurs when the supply of oxygenated blood in the body is restricted. We seek to reverse this restriction through the development and formation of new blood vessels. AMR-001 is our most clinically advanced product candidate in our CD34 Cell Program and is being developed to treat damaged heart muscle following an acute myocardial infarction (heart attack) ("AMI"). In December 2013, the Company completed enrollment in its PreSERVE AMI study. PreSERVE AMI is a randomized, double-blinded, placebo-controlled Phase 2 clinical trial testing AMR-001, an autologous (donor and recipient are the same) adult stem cell product for the treatment of patients with left ventricular dysfunction following acute ST segment elevation myocardial infarction (STEMI). With infusion of the target population of 160 patients complete, the last patient primary endpoint follow-up for this study is expected in June 2014 followed by data lock and analysis with a submission for a possible presentation of the study at the American Heart Association's Scientific Sessions to be held November 15-19, 2014. If approved by Food and Drug Administration (the "FDA ") and/or other worldwide regulatory agencies following successful completion of further trials, AMR-001 would address a significant medical need for which there is currently no effective treatment, potentially improving longevity and quality of life for those suffering a STEMI, and positioning the Company to capture a meaningful share of this worldwide market. We also expect to initiate a Phase 2 clinical trial for chronic heart failure in Europe in 2014 and are conducting preclinical studies in traumatic brain injury for which we expect data in the second half of 2014.

Another platform technology we are developing utilizes T Regulatory Cells ("Tregs") to treat diseases caused by imbalances in the immune system. In collaborating with Becton-Dickinson and the University of California, San Francisco, we are utilizing this technology platform of our majority-owned subsidiary, Athelos Corporation ("Athelos"), to restore immune balance by enhancing Treg cell number and function. Tregs are a natural part of the human immune system and regulate the activity of T effector cells, the cells that are responsible for protecting the body from viruses and other foreign antigen exposure. When Tregs function properly, only foreign materials are attacked by T effector cells. In autoimmune disease it is thought that deficient Treg activity permits the T effector cells to attack the body's own tissues. We plan to initiate a Phase 2 study of Treg based therapeutics to treat type 1 diabetes in 2014. We also plan to initiate a Phase 1 study in Canada of Treg based therapeutics in support of a steroid resistant asthma indication in 2014.

Pre-clinical assets include our VSEL^TM (Very Small Embryonic Like) Technology regenerative medicine platform. Regenerative medicine holds the promise of improving clinical outcomes and reducing overall healthcare costs. We are working on a Department of Defense funded study of VSELs^TM for the treatment of chronic wounds. Other preclinical work with VSELs^TMincludes exploring macular degeneration as a target indication.

Progenitor Cell Therapy, LLC ("PCT") is a contract manufacturer that generates revenue. This wholly owned subsidiary, which we acquired in 2011, is an industry leader in providing high quality manufacturing capabilities and support to developers of cell-based therapies to enable them to improve efficiencies and profitability and reduce capital investment for their own development activities. Since its inception more than 15 years ago, PCT has provided pre-clinical and clinical current Good Manufacturing Practice (“cGMP”) development and manufacturing services to more than 100 clients. PCT has experience advancing regenerative medicine product candidates from product inception through rigorous quality standards all the way through to human testing, Biologic License Application ("BLA") filing and FDA product approval. PCT's core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, engineering and innovation services, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services. PCT has two cGMP, state-of-the art cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. The Company is pursuing commercial expansion of our manufacturing operations both in the U.S. and internationally.

Effective March 31, 2012, we no longer operated in the former Regenerative Medicine – China segment, which is now reported in discontinued operations (see Note 15). On November 13, 2012, we completed the sale of our 51% interest in Suzhou Erye, which represented the operations in our former Pharmaceutical Manufacturing - China segment, and is also reported in discontinued operations (see Note 15). As a result, we currently operate in a single reporting segment - Cell Therapy, which will focus on contract development and manufacturing and cell therapy development programs.

We believe that NeoStem is ideally positioned to lead the cell therapy industry.

Basis of Presentation

The accompanying Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles”) and include the accounts of the Company and its wholly owned and partially owned subsidiaries, the operations of our former Regenerative Medicine - China segment through the deconsolidation date on March 31, 2012 (see Note 15), and the operations of our former Pharmaceutical Manufacturing - China segment through November 13, 2012, the date on which the segment was sold (see Note 15). These former segments are reported in discontinued operations. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, include all normal and recurring adjustments considered necessary to present fairly the Company's financial position as of December 31, 2013 and 2012, and the results of its operations and its cash flows for the years then ended.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Examples of estimates include the fair value of goodwill and/or potential goodwill impairments for our reporting units, useful lives of our tangible and intangible assets, allowances for doubtful accounts, and stock-based compensation forfeiture rates. An example of an assumption includes the potential outcome of future tax consequences of events that have been recognized in our financial statements or tax returns. Accordingly, actual results could differ from those estimates and assumptions.

Reclassifications

Certain reclassifications have been made to the Consolidated Financial Statements and Notes to the Consolidated Financial Statements for the year ended December 31, 2012 to conform to the presentation for the year ended December 31, 2013.

Principles of Consolidation

The Consolidated Financial Statements include the accounts of NeoStem, Inc. and its wholly owned and partially owned subsidiaries and affiliates as listed below, as well as the operations of our former Regenerative Medicine - China segment through the deconsolidation date on March 31, 2012 (see Note 15), and the operations of our former Pharmaceutical Manufacturing - China segment through November 13, 2012, representing the date which the segment was sold (see Note 15). These former segments are reported in discontinued operations.



Entity	Percentage of Ownership	Location
NeoStem, Inc.	Parent Company	United States of America
NeoStem Therapies, Inc.	100%	United States of America
Stem Cell Technologies, Inc.	100%	United States of America
Amorcyte, LLC	100%	United States of America
Progenitor Cell Therapy, LLC (PCT)	100%	United States of America
NeoStem Family Storage, LLC	100%	United States of America
Athelos Corporation (1)	88.5%	United States of America
PCT Allendale, LLC	100%	United States of America

(1) Pursuant to the Stock Purchase Agreement signed in March 2011, our initial ownership in Athelos was 80.1%, and Becton Dickinson's ("BD") initial minority ownership was 19.9%. Per the Agreement, BD will be diluted based on new investment in Athelos by us (subject to certain anti-dilution provisions). As of December 31, 2013, BD's ownership interest in Athelos was decreased to 11.5%, and our ownership increased to 88.5%. As a result in the change in ownership, approximately $0.3 million was transferred from additional paid in capital to non-controlling interests.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2013

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies [Text Block]

Summary of Significant Accounting Policies

Cash and Cash Equivalents

Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.

Concentration of Risks

For the year ended December 31, 2013, two customers represented 19% and 11%, respectively, of total revenues recognized.

Accounts Receivable

Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. The Company applies judgment in connection with establishing the allowance for doubtful accounts. Specifically, the Company analyzes the aging of accounts receivable balances, historical bad debts, customer concentration and credit-worthiness, current economic trends and changes in the Company’s customer payment terms. Significant changes in customer concentrations or payment terms, deterioration of customer credit-worthiness or weakening economic trends could have a significant impact on the collectability of the receivables and the Company’s operating results. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. Management regularly reviews the aging of receivables and changes in payment trends by its customers, and records a reserve when it believes collection of amounts due are at risk.

Inventories

The Company, through its PCT subsidiary, regularly enters into contracts with clients for services that have multiple stages and are dependent on one another to complete the contract and recognize revenue. The Company's inventory represents work in process for costs incurred on such projects at PCT that have not been completed. The Company reviews these projects periodically to determine that the value of each project is stated at the lower of cost or market.

Property, Plant, and Equipment

The cost of property, plant and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property, plant and equipment are as follows:



Building and improvements	25-30 years
Machinery and equipment	8-12 years
Lab equipment	5-7 years
Furniture and fixtures	5-12 years
Software	3-5 years
Leasehold improvements	Life of lease

Goodwill and Other Intangible Assets

Goodwill is the excess of purchase price over the fair value of identified net assets of businesses acquired. The Company’s intangible assets with an indefinite life are related to in process research and development ("IPR&D") for AMR-001, the clinical candidate acquired in the Amorcyte acquisition, as the Company expects this research and development to provide the Company with substantial benefit for a period that extends beyond the foreseeable horizon. Intangible assets with indefinite useful lives are measured at their respective fair values as of the acquisition date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Intangible assets related to IPR&D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.

The Company reviews goodwill and indefinite-lived intangible assets at least annually for possible impairment. Goodwill and indefinite-lived intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. The Company tests its goodwill and indefinite-lived intangible assets each year on December 31. The Company reviews the carrying value of goodwill and indefinite-lived intangible assets utilizing a discounted cash flow model, and, where appropriate, a market value approach is also utilized to supplement the discounted cash flow model. The Company makes assumptions regarding estimated future cash flows, discount rates, long-term growth rates and market values to determine each reporting unit’s estimated fair value. If these estimates or related assumptions change in the future, the Company may be required to record impairment charges. In accordance with it's accounting policy, the Company tested goodwill for impairment as of December 31, 2013 and 2012 for its two reporting units, and concluded there was no risk of failing step 1 of the goodwill impairment testing evaluation.

Amortized intangible assets consist of customer lists, manufacturing technology, and tradename, as well as patents and rights associated primarily with the VSEL™ Technology. These intangible assets are amortized on a straight line basis over their respective useful lives.

Evaluation of Long-lived Assets

The Company reviews long-lived assets and finite-lived intangibles assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. No events were noted in 2013 or 2012.

Recognizing and Measuring Assets Acquired and Liabilities Assumed in Business Combinations at Fair Value

The Company accounts for acquired businesses using the purchase method of accounting, which requires that assets acquired and liabilities assumed be recorded at date of acquisition at their respective fair values. The consolidated financial statements and results of operations reflect an acquired business after the completion of the acquisition. The fair value of the consideration paid, including contingent consideration, is assigned to the underlying net assets of the acquired business based on their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Amounts allocated to IPR&D are included on the balance sheet . Intangible assets, including IPR&D assets upon successful completion of the project and approval of the product, are amortized on a straight-line basis to amortization expense over the expected life of the asset. Significant judgments are used in determining the estimated fair values assigned to the assets acquired and liabilities assumed and in determining estimates of useful lives of long-lived assets. Fair value determinations and useful life estimates are based on, among other factors, estimates of expected future net cash flows, estimates of appropriate discount rates used to present value expected future net cash flow streams, the timing of approvals for IPR&D projects and the timing of related product launch dates, the assessment of each asset’s life cycle, the impact of competitive trends on each asset’s life cycle and other factors. These judgments can materially impact the estimates used to allocate acquisition date fair values to assets acquired and liabilities assumed and the resulting timing and amount charged to, or recognized in current and future operating results. For these and other reasons, actual results may vary significantly from estimated results.

The Company determines the acquisition date fair value of contingent consideration obligations based on a probability-weighted income approach derived from revenue estimates, post-tax gross profit levels and a probability assessment with respect to the likelihood of achieving contingent obligations including contingent payments such as milestone obligations, royalty obligations and contract earn-out criteria, where applicable. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in fair value measurement accounting. The resultant probability-weighted cash flows are discounted using an appropriate effective annual interest rate. At each reporting date, the contingent consideration obligation will be revalued to estimated fair value and changes in fair value will be reflected as income or expense in our consolidated statement of operations. Changes in the fair value of the contingent consideration obligations may result from changes in discount periods and rates, changes in the timing and amount of revenue estimates and changes in probability assumptions with respect to the likelihood of achieving the various contingent payment obligations. Changes in assumptions utilized in our contingent consideration fair value estimates could result in an increase or decrease in our contingent consideration obligation and a corresponding charge to operating loss.

Share-Based Compensation

The Company expenses all share-based payment awards to employees, directors, advisors and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Advisor and consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of certain share-based awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. The fair value of the Company’s restricted stock and restricted stock units is based on the closing market price of the Company’s common stock on the date of grant.

Loss Per Share

Basic loss per share is based on the weighted effect of all common shares issued and outstanding, and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share, which is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding, is not presented as such potentially dilutive securities are anti-dilutive in all periods presented due to losses incurred.

Derivatives

Derivative instruments, including derivative instruments embedded in other contracts, are recorded on the balance sheet as either an asset or liability measured at its fair value. Changes in the fair value of derivative instruments are recognized currently in results of operations unless specific hedge accounting criteria are met. The Company has not entered into hedging activities to date. Changes in the derivative value are recorded as other income (expense) on the consolidated statements of operations.

Income Taxes

The Company recognizes (a) the amount of taxes payable or refundable for the current year and (b) deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. The Company continues to evaluate the accounting for uncertainty in tax positions. The guidance requires companies to recognize in their financial statements the impact of a tax position if the position is more likely than not of being sustained if the position were to be challenged by a taxing authority. The position ascertained inherently requires judgment and estimates by management. The Company recognizes interest and penalties as a component of income tax expense.

Foreign Currency Translation

Results of the the Company’s former Chinese operating segments were translated at the average exchange rates during the period, and assets and liabilities were translated at the closing rate at the end of each reporting period. Cash flows were also translated at average exchange rates for the period, therefore, amounts reported on the consolidated statement of cash flows did not necessarily agree with changes in the corresponding balances on the consolidated balance sheet.

Treasury Stock

Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.

Revenue Recognition

Clinical Services: The Company recognizes revenue for its (i) cell process development and (ii) cell manufacturing services based on the terms of individual contracts.

Revenues associated with cell process development services generally contain multiple stages that do not have stand-alone values and are dependent upon one another, and are recognized as revenue on a completed contract basis. We recognize revenues for cell development services when all of the following conditions are met:


•	persuasive evidence of an arrangement exists;


•	delivery has occurred or the services have been rendered;


•	the fee is fixed or determinable; and


•	collectability is probable.

The Company considers signed contracts as evidence of an arrangement. The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the payment terms are subject to refund or adjustment. The Company assesses cash collectability based on a number of factors, including past collection history with the client and the client's creditworthiness. If the Company determines that collectability is not reasonably assured, it defers revenue recognition until collectability becomes reasonably assured, which is generally upon receipt of the cash. The Company's arrangements are generally non-cancellable, though clients typically have the right to terminate their agreement for cause if the Company materially fails to perform.

Cell manufacturing services are generally distinct arrangements whereby the Company is paid for time and materials or for fixed monthly amounts. Revenue is recognized when efforts are expended or contractual terms have been met.

Some client agreements include multiple elements, comprised of cell process development and cell manufacturing services. The Company believes that cell process development and cell manufacturing services each have stand-alone value because these services can be provided separately by other companies. In accordance with ASC Update No. 2009-13, “Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements,” the Company (1) separates deliverables into separate units of accounting when deliverables are sold in a bundled arrangement and (2) allocates the arrangement's consideration to each unit in the arrangement based on its relative selling price.

Clinical Services Reimbursements: The Company separately charges the customers for the expenses associated with certain consumable resources (reimbursable expenses) that are specified in each clinical services contract. On a monthly basis, the Company bills customers for reimbursable expenses and immediately recognizes these billings as revenue, as the revenue is deemed earned as reimbursable expenses are incurred. For the year ended December 31, 2013 and 2012, clinical services reimbursements were $2.1 million and $3.5 million, respectively.

Processing and Storage Services: The Company recognizes revenue related to the collection and cryopreservation of cord blood and autologous adult stem cells when the cryopreservation process is completed which is approximately twenty-four hours after cells have been collected. Revenue related to advance payments of storage fees is deferred and recognized ratably over the period covered by the advance payments.

Research and Development Costs

Research and development (“R&D”) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.

To further drive the Company’s cell therapy initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company’s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.

Cash and Cash Equivalents	12 Months Ended
Cash and Cash Equivalents	Dec. 31, 2013
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents [Text Block]	Cash and Cash Equivalents As of December 31, 2013 and December 31, 2012, the Company had cash and cash equivalents of approximately $46.1 million and $13.7 million, respectively, including bank deposits of approximately $0.7 million and $0.8 million, respectively, covered by the Federal Deposit Insurance Corporation.

- Definition

The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 6.H.3)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13728-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7
-Footnote 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section H
-Subsection 3

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 8, 9, 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Inventories	12 Months Ended
Inventories	Dec. 31, 2013
Inventories [Abstract]
Inventory Disclosure [Text Block]	Inventories Inventories, representing work in process for costs incurred on projects at PCT that have not been completed, were $1.3 million and $1.1 million as of December 31, 2013 and December 31, 2012, respectively. The Company also has deferred revenue of approximately $1.5 million and $1.2 million of billings received as of December 31, 2013 and December 31, 2012, respectively, related to these contracts.

Property, Plant & Equipment

12 Months Ended

Dec. 31, 2013

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

Property, Plant and Equipment

Property, plant, and equipment consisted of the following (in thousands):



	December 31,
	2013			2012
Building and improvements	$	11,229.9		$	9,897.8
Machinery and equipment	58.2			39.5
Lab equipment	2,743.7			1,800.6
Furniture and fixtures	958.0			683.7
Software	203.1			99.5
Leasehold improvements	674.1			654.5
Property, plant and equipment, gross	15,867.0			13,175.6
Accumulated depreciation	(3,022.8		)	(2,022.5		)
Property, plant and equipment, net	$	12,844.2		$	11,153.1

The Company’s results included depreciation expense of approximately $1.0 million and $1.0 million for the years ended December 31, 2013 and December 31, 2012, respectively.

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

Loss Per Share

12 Months Ended

Dec. 31, 2013

Loss Per Share [Abstract]

Loss Per Share [Text Block]

Loss Per Share

For the year ended December 31, 2013 and 2012, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of loss per share. At December 31, 2013 and 2012, the Company excluded the following potentially dilutive securities:



	December 31,
	2013	2012
Stock Options	2,932,191	2,168,668
Warrants	4,898,266	5,528,761
Restricted Shares	78,500	34,250

Fair Value Measurements

12 Months Ended

Dec. 31, 2013

Fair Value Measurements [Abstract]

Fair Value Measurements [Text Block]

Fair Value Measurements

Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:

Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.

Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.

The Company determined the fair value of the embedded derivative liabilities and warrant derivative liabilities to be level 3 inputs. These inputs require material subjectivity because value is derived through the use of a lattice model that values the derivatives based on probability weighted discounted cash flows. The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2013, and December 31, 2012 (in thousands):



	December 31, 2013
	Fair Value Measurements Using Fair Value Hierarchy
	Level 1		Level 2		Level 3
Warrant derivative liabilities	$	—	$	—	$	23.2
Contingent consideration	—		—		9,450.0



	December 31, 2012
	Fair Value Measurements Using Fair Value Hierarchy
	Level 1		Level 2		Level 3
Warrant derivative liabilities	$	—	$	—	$	101.2
Contingent consideration	—		—		7,550.0

Contingent consideration was recognized on October 17, 2011 in connection with the Company's acquisition of Amorcyte. The contingent consideration obligations relates to earn out payments equal to 10% of the net sales of Amorcyte’s lead product candidate AMR-001 (in the event of and following the date of first commercial sale of AMR-001), provided that in the event NeoStem sublicenses AMR-001, the applicable earn out payment will be equal to 30% of any sublicensing fees, and provided further that NeoStem will be entitled to recover direct out-of-pocket clinical development costs not previously paid or reimbursed and any costs, expenses, liabilities and settlement amounts arising out of claims of patent infringement or otherwise challenging Amorcyte’s right to use intellectual property, by reducing any earn out payments due by 50% until such costs have been recouped in full (the “Earn Out Payments”).

The fair value of contingent consideration obligations is determined using Level 3 inputs, and is based on a discounted cash flow model using a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on our own assumptions and experience. We base the timing to complete the development and approval of this product on the current development stage of the product and the inherent difficulties and uncertainties in developing a product candidate, such as obtaining U.S. Food and Drug Administration (FDA) and other regulatory approvals. In determining the probability of regulatory approval and commercial success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period. Changes in the fair value of the contingent consideration obligations are recorded in our consolidated statement of operations. The contingent consideration fair value increased from $7.6 million as of December 31, 2012 to $9.5 million as of December 31, 2013. The change in estimated fair value is based on the Company's update of the discounted cash flow model using a probability-weighted income approach, taking into account a 18% discount rate, revised collaboration assumptions, and assumptions of the market opportunity and development costs, and the impact of the time progression through the Phase 2 clinical trial from December 31, 2012 to December 31, 2013.

For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the year ended December 31, 2013 by type of instrument (in thousands):



	Year Ended
	December 31, 2013
	Warrants			Contingent Consideration
Beginning liability balance	$	101.2		$	7,550.0
Change in fair value recorded in earnings	(78.0		)	1,900.0
Ending liability balance	$	23.2		$	9,450.0

For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the year ended December 31, 2012 by type of instrument (in thousands):



	Year Ended
	December 31, 2012
	Embedded Derivatives			Warrants		Contingent Consideration
Beginning liability balance	$	391.7		$	82.7	$	3,130.0
Change in fair value recorded in earnings	(391.7		)	18.5		4,420.0
Ending liability balance	$	—		$	101.2	$	7,550.0

Some of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate fair value due to their liquid or short-term nature, such as cash and cash equivalents, accounts receivable, accounts payable, and notes payable.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Goodwill and Other Intangible Assets

12 Months Ended

Dec. 31, 2013

Goodwill and Other Intangible Assets [Abstract]

Goodwill and Intangible Assets [Text Block]

Goodwill and Other Intangible Assets

The Company's goodwill was $11.1 million as of December 31, 2013 and December 31, 2012, respectively.

The Company's intangible assets and related accumulated amortization as of December 31, 2013 and December 31, 2012 consisted of the following (in thousands):



		December 31, 2013							December 31, 2012
	Useful Life	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer list	10 years	$	1,000.0	$	(295.1	)	$	704.9	$	1,000.0	$	(195.1	)	$	804.9
Manufacturing technology	10 years	3,900.0		(1,150.9		)	2,749.1		3,900.0		(760.9		)	3,139.1
Tradename	10 years	800.0		(236.1		)	563.9		800.0		(156.1		)	643.9
In process R&D	Indefinite	9,400.0		—			9,400.0		9,400.0		—			9,400.0
VSEL patent rights	19 years	669.0		(211.3		)	457.7		669.0		(176.1		)	492.9
Total Intangible Assets		$	15,769.0	$	(1,893.4	)	$	13,875.6	$	15,769.0	$	(1,288.2	)	$	14,480.8

Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):



	Year Ended December 31,
	2013		2012
Cost of revenue	$	390.0	$	390.0
Research and development	35.2		35.2
Selling, general and administrative	180.0		180.0
Total	$	605.2	$	605.2

Estimated intangible amortization expense on an annual basis for the succeeding five years is as follow (in thousands):



2014	$	605.2
2015	605.2
2016	605.2
2017	605.2
2018	605.2
Thereafter	10,849.6
	$	13,875.6

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Accrued Liabilities

12 Months Ended

Dec. 31, 2013

Accrued Liabilities [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Accrued Liabilities

Accrued liabilities were as follow (in thousands):



	December 31,
	2013		2012
Salaries, employee benefits and related taxes	$	2,325.8	$	1,597.2
Professional fees	544.8		606.6
License fees	500.0		—
Other	647.4		81.0
	$	4,018.0	$	2,284.8

Debt	12 Months Ended
Debt	Dec. 31, 2013
Debt [Abstract]
Debt Disclosure [Text Block]	Debt Notes Payable As of December 31, 2013 and December 31, 2012, the Company had notes payable of approximately $0.9 million and $0.4 million, respectively. The notes relate to certain insurance policies and equipment financings, require monthly payments, and mature within one to three years. Mortgages Payable In October 2007, PCT issued a note to borrow $3.1 million (the “First Mortgage”) in connection with its $3.8 million purchase of condominium units in an existing building in Allendale, New Jersey (the “Property”) that PCT uses as a laboratory and stem cell processing facility. The First Mortgage is payable in 239 consecutive monthly payments of principal and interest, based on a 20 year amortization schedule; and one final payment of all outstanding principal plus accrued interest then due. The current monthly installment is $20,766, which includes interest at an initial rate of 5.00%; the interest rate and monthly installments payments are subject to adjustment on October 1, 2017. On that date, upon prior written notice, the lender has the option to declare the entire outstanding principal balance, together with all outstanding interest, due and payable in full. The First Mortgage is secured by substantially all of the assets of PCT, including a first mortgage on the Property and assignment of an amount approximately equal to eighteen months debt service held in escrow. The Note matures on October 1, 2027 if not called by the lender on October 1, 2017. The First Mortgage was subject to certain debt service coverage and total debt to tangible net worth financial covenant ratios measured semi-annually. The outstanding balance was approximately $2.5 million and $2.6 million at December 31, 2013 and December 31, 2012, respectively, of which $126,700 is payable within twelve months as of December 31, 2013. In December 2010 PCT Allendale, a wholly-owned subsidiary of PCT, entered into a note for a second mortgage in the amount of $1 million (the "Second Mortgage") on the Allendale Property with TD Bank, N.A. This Second Mortgage is guaranteed by PCT, DomaniCell (a wholly-owned subsidiary of PCT, now known as NeoStem Family Storage, LLC), Regional Cancer Care Associates LLC and certain of its partners were subject to an annual financial covenant starting December 31, 2011. PCT was not in compliance with such covenants at the measurement date of December 31, 2012, and obtained a covenant waiver letter from the lender for each period. The Second Mortgage is for 124 months at a fixed rate of 6% for the first 64 months. The loan is callable for a certain period prior to the interest reset date. The outstanding balance was approximately $0.8 million and $0.8 million at December 31, 2013 and December 31, 2012, respectively, of which $86,400 is payable within twelve months as of December 31, 2013. In December 2013, the Company modified both the First Mortgage and Second Mortgage with TD Bank, N.A., whereby (i) prior debt service coverage and total debt to tangible net worth financial covenant ratios were replaced with a minimum unencumbered liquidity covenant, and (ii) prior guarantors were released (see Note 16) and replaced with NeoStem, PCT, and NeoStem Family Storage. Prior to this modification, PCT was not in compliance with such covenants at the June 30, 2012, December 31, 2012, and June 30, 2013 measurement dates, and as a result, classified the entire First Mortgage and Second Mortgage balances as a current liability. PCT also obtained a covenant waiver letter for each period. Subsequent to the modification, as of December 31, 2013, the Company is in compliance with the new minimum unencumbered liquidity covenant, and as a result, will only report mortgage payments due within twelve months as a current liability.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

Preferred Stock	12 Months Ended
Preferred Stock	Dec. 31, 2013
Preferred Stock [Abstract]
Preferred Stock [Text Block]	Preferred Stock Convertible Redeemable Series E 7% Preferred Stock On November 19, 2010, the Company sold 10,582,011 Preferred Offering Units consisting of (i) one share (“Preferred Share”) of Series E 7% Senior Convertible Preferred Stock (the “Series E Preferred Stock”), par value $0.01 per share, of the Company, (ii) a warrant to purchase 0.25 of a share of common stock (consisting of at issuance an aggregate of 132,249 warrants, adjusted to an aggregate of 222,446 as of December 31, 2013); and (iii) 0.0155 of a share of common stock (an aggregate of 16,442 common shares). Each Preferred Offering Unit was priced at $0.945 and total gross and net proceeds received by the Company were $10.0 million and $8.9 million, respectively. Monthly dividend and principal payments began in March 2011, and continued each month thereafter with the final payment due in May 2013. In October 2012, the Company completed the redemption of all 2,351,558 Series E Preferred Stock shares then remaining outstanding, for an aggregate cash redemption price of approximately $3.4 million, $2.5 million of which was funded by money placed into escrow when the Series E Preferred stock was issued in November 2010. The cash redemption included the repayment of $3.1 million outstanding principal, an additional early redemption premium of $0.2 million, which was included in dividends, and $36,000 of accrued interest. The Company recorded the fair value of the warrants as a short-term derivative liability as of December 31, 2013, and long-term derivative liability as of December 31,2012. The fair values of the warrant derivatives as of December 31, 2013 and December 31, 2012 were $23,200 and $101,200, respectively. The Company reports changes in the fair value of the warrant derivative in earnings within other income (expense), net (see Note 7).

Shareholders' Equity

12 Months Ended

Dec. 31, 2013

Shareholders’ Equity [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Stockholders' Equity

Reverse Stock Split

On June 28, 2013, pursuant to prior shareholder authorization, the Company’s board of directors unanimously approved a 1-for-10 reverse stock split of the Company’s common stock, which the Company effected on July 16, 2013. All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods to give retroactive effect to the reverse stock split. The shares of common stock retained a par value of $0.001 per share. Accordingly, the stockholders’ deficit reflects the reverse stock split by reclassifying from “common stock” to “Additional paid-in capital” an amount equal to the par value of the decreased shares resulting from the reverse stock split.

Equity Plans

The Company's 2003 Equity Participation Plan (the “2003 Equity Plan”) expired in 2013 and accordingly, equity awards under the 2003 Equity Plan can no longer be issued. Prior to its expiration, the Company’s 2003 Equity Participation Plan had permitted the grant of share options and shares to the Company's employees, directors, consultants and advisors for up to 250,000 shares of common stock as stock-based compensation. The 2009 Equity Compensation Plan (the “2009 Equity Plan”) makes up to 5,995,000 shares of common stock of the Company (as of December 31, 2013) available for issuance to employees, consultants, advisors and directors of the Company and its subsidiaries pursuant to incentive or non-statutory stock options, restricted and unrestricted stock awards and stock appreciation rights.

All stock options under the 2003 Equity Plan were granted and the 2009 Equity Plan are granted at the fair market value of the common stock at the grant date. Stock options vest either on the date of grant, ratably over a period determined at time of grant, or upon the accomplishment of specified business milestones, and generally expire 2, 3, or 10 years from the grant date depending on the status of the recipient as a consultant, advisor, employee or director of the Company.

The 2009 Equity Plan was originally adopted by the stockholders of the Company on May 8, 2009. On October 29, 2009, the stockholders of the Company approved an amendment to the 2009 Equity Plan to increase the number of shares of common stock available for issuance thereunder from 380,000 to 975,000. At the 2010 Annual Meeting of Stockholders of the Company held on June 2, 2010, the stockholders approved an amendment to increase this number to 1,375,000. At a Special Meeting of Stockholders of the Company held on January 18, 2011, the stockholders approved an amendment to increase this number to 1,775,000 . At the 2011 Annual Meeting of Stockholders of the Company held on October 14, 2011, the stockholders approved an amendment to increase this number to 2,375,000. At the 2012 Annual Meeting of Stockholders of the Company held on October 5, 2012, the stockholders approved an amendment to (i) merge the 570,000 shares reserved for issuance under the Company's 2009 Non-U.S. Based Equity Compensation Plan (the "Non-U.S. Plan") with and into the 2009 Equity Plan, and (ii) increase by 450,000 the aggregate number of shares authorized for issuance under the 2009 Equity Plan (the “2009 Amended & Restated Equity Plan”). At the Company's 2013 Annual Meeting held October 3, 2013, the Company's stockholders approved an amendment to the 2009 Amended & Restated Equity Plan to increase the number of shares authorized for issuance thereafter by 2,600,000. The Non-U.S. Plan was originally adopted by the stockholders of the Company on October 29, 2009, and was subsequently amended on June 2, 2010 to increase the shares from 470,000 to 870,000, and on October 14, 2011 to decrease the shares to 570,000, prior to the merger into the 2009 Equity Plan.

The number of remaining shares authorized to be issued under the various equity plans are as follows:



	2003 Equity Plan		2009 Equity Plan
Shares Authorized for Issuance	250,000		5,995,000
Outstanding Stock Options	(136,480	)	(2,795,711	)
Exercised Stock Options	(9,250	)	(31,869	)
Restricted stock or equity grants issued under Equity Plans	(88,993	)	(595,852	)
Shares Expired	(15,277	)	—
Total common shares remaining to be issued under the Equity Plans	—		2,571,568

The Company adopted an employee stock purchase plan effective January 1, 2013, and authorized 500,000 shares under the plan. The plan has two six-month offering periods per year under which eligible employees may contribute up to 15% of their compensation toward the purchase of the Company's common stock per offering period (with a $25,000 cap per calender year). The employee's purchase price is equal to (i) 85% of the closing price of a share of the Company's common stock on the enrollment date of such offering period or (ii) 85% of the closing price of a share of the Company's Common Stock on the Exercise Date of such Offering Period, whichever is lower. During the year ended December 31, 2013, 23,052 shares were issued under the employee stock purchase plan. At December 31, 2013, the Company had 476,948 shares of the Company's common stock available for future grant in connection with these plans.

Equity Issuances

In September 2011, the Company entered into a common stock Purchase Agreement (the “Prior Purchase Agreement”) with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), which provides that, subject to certain terms and conditions, Aspire Capital was committed to purchase up to an aggregate of $20.0 million worth of shares of the Company’s common stock over the 24-month term of the Prior Purchase Agreement. At the Company’s discretion, it may present Aspire Capital with purchase notices under the Prior Purchase Agreement from time to time, to purchase the Company’s common stock, provided certain price and other requirements are met. The purchase price for the shares of stock was based upon one of two formulas set forth in the Prior Purchase Agreement depending on the type of purchase notice we submit to Aspire Capital from time to time, and was be based on market prices of the Company’s common stock (in the case of regular purchases) or a discount of 5% applied to volume weighted average prices (in the case of VWAP purchases), in each case as determined by parameters defined in the agreement. As consideration for entering into the Prior Purchase Agreement, effective September 30, 2011, we issued 99,010 shares of our common stock to Aspire Capital (the “Commitment Shares”). The issuance of shares of common stock to Aspire Capital pursuant to the Prior Purchase Agreement, including the Commitment Shares, and the sale of those shares from time to time by Aspire Capital to the public, are covered by a shelf registration statement on Form S-3.

In August 2012, the Company and Aspire entered into an amendment to the Prior Purchase Agreement dated September 28, 2011, providing for an extension of the 24-month term of the Prior Purchase Agreement until September 30, 2015. Pursuant to the amendment, we agreed to issue to Aspire a five-year warrant to purchase up to 161,290 shares of our common stock at an exercise price of $6.00 per share (the closing price of our common stock on the date the amendment was executed).

For the year ended December 31, 2013, the Company issued 1.6 million shares of common stock under the provisions of its equity line of credit with Aspire for gross proceeds of approximately $11.1 million. As of December 31, 2013, the remaining amount available to the Company under the Prior Purchase Agreement was $5.6 million.

In April 2013, the Company completed an underwritten offering of 2.0 million shares of the Company's common stock, at a public offering price of $5.00 per share. The underwriters also exercised their entire over-allotment option of 0.3 million shares. The Company received gross proceeds of $11.5 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company.

In October 2013, the Company completed an underwritten offering of 5.0 million shares of the Company's common stock, at a public offering price of $7.00 per share. The underwriters also exercised their entire over-allotment option of 0.75 million shares. The Company received gross proceeds of $40.3 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company.

Option Exercises

During the year ended ended December 31, 2013, option holders exercised an aggregate of 0.03 million options at exercise prices between $4.00 and $5.90 per share for gross proceeds of approximately $0.2 million.

Warrant Exercises

To raise capital on terms that we deemed favorable, during the year ended December 31, 2013, the Board authorized certain inducements to warrant holders to exercise outstanding common stock purchase warrants significantly before their expiration dates. The Company determined in each instance that such inducements were modifications of equity instruments, and an incremental fair value of the inducement was determined using the Black-Scholes option pricing model.

During the year ended ended December 31, 2013, warrant holders exercised an aggregate of 0.6 million warrants at exercise prices between $5.10 and $7.40 per share for gross proceeds of approximately $3.0 million. As an inducement to exercise, we paid certain warrant holders $0.30 per share upon each exercise.

Stock Options and Warrants

The following table summarizes the activity for stock options and warrants for the years ended December 31, 2013 and December 31, 2012:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2012	2,168,668		$	12.85	6.8	$	1,658.1	5,528,761		$	15.65	3.6	$	1,300.0

Changes during the Year:
Granted	959,167		$	7.01				86,250		$	6.66
Exercised	(31,369	)	$	4.80				(563,166	)	$	5.38
Forfeited	(89,412	)	$	5.54				(17,500	)	$	14.20
Expired	(74,863	)	$	15.40				(136,079	)	$	20.15
Outstanding at December 31, 2013	2,932,191		$	11.19	6.8	$	1,658.1	4,898,266		$	16.50	2.6	$	1,811.0
Vested at December 31, 2013 or expected to vest in the future	2,816,138		$	11.36	6.7	$	1,604.0	4,884,957		$	16.35	2.6	$	1,811.0
Exercisable at December 31, 2013	2,231,869		$	12.14	6.4	$	1,283.3	4,780,658		$	15.41	2.6	$	1,811.0

The total intrinsic value of stock options exercised during the years ended December 31, 2013 and December 31, 2012 was $104,360 and $0, respectively.

During the year ended December 31, 2013 and 2012, the Company issued warrants for services as follows ($ in thousands, except share data):



	Year Ended December 31,
	2013		2012
Number of Common Stock Purchase Warrants Issued	40,407		41,969
Value of Common Stock Purchase Warrants Issued	$	149.9	$	172.2

Restricted Stock

During the year ended December 31, 2013 and 2012, the Company issued restricted stock for services as follows ($ in thousands, except share data):



	Year Ended December 31,
	2013		2012
Number of Restricted Stock Issued	514,700		229,553
Value of Restricted Stock Issued	$	3,360.0	$	1,325.1

The weighted average estimated fair value of restricted stock issued for services in the year ended December 31, 2013 and 2012 was $6.53 and $5.77 per share, respectively. The fair value of the restricted stock was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock issuances are generally within one year.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section B
-Paragraph 7, 11A
-Chapter 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Share-Based Compensation (Notes)

12 Months Ended

Dec. 31, 2013

Share-based Compensation [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Share-Based Compensation

Share-based Compensation

We utilize share-based compensation in the form of stock options, warrants and restricted stock. The following table summarizes the components of share-based compensation expense for the year ended December 31, 2013 and 2012 ($ in thousands):



	Year Ended December 31,
	2013		2012
Cost of goods sold	$	314.0	$	195.0
Research and development	822.2		432.9
Selling, general and administrative	5,702.5		6,084.6
Total share-based compensation expense	$	6,838.7	$	6,712.5

Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at December 31, 2013 were as follows ($ in thousands):



	Stock Options		Warrants		Restricted Stock
Unrecognized compensation cost	$	2,422.2	$	55.6	$	335.6
Expected weighted-average period in years of compensation cost to be recognized	3.51		1.54		0.38

Total fair value of shares vested and the weighted average estimated fair values of shares grant for the year ended December 31, 2013 and 2012 were as follows ($ in thousands):



	Stock Options				Warrants
	Year Ended December 31,				Year Ended December 31,
	2013		2012		2013		2012
Total fair value of shares vested	$	3,375.7	$	5,408.0	$	129.0	$	171.6
Weighted average estimated fair value of shares granted	4.29		3.63		3.71		4.10

Valuation Assumptions

The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company’s stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.

The range of assumptions made in calculating the fair values of stock options and warrants was as follow:



	Stock Options		Warrants
	Year Ended December 31,		Year Ended December 31,
	2013	2012	2013	2012
Expected term - minimum (in years)	1	2	2	2
Expected term - maximum (in years)	10	10	5	5
Expected volatility - minimum	61%	73%	73%	76%
Expected volatility - maximum	79%	84%	79%	83%
Expected dividend yield	—	—	—	—
Risk-free interest rate - minimum	0.13%	0.28%	0.32%	0.27%
Risk-free interest rate - maximum	2.67%	1.99%	1.73%	0.88%

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Income Taxes

12 Months Ended

Dec. 31, 2013

Income Taxes [Abstract]

Income Tax Disclosure [Text Block]

Income Taxes

The provision (benefit) for income taxes is based on loss from operations before provision for income taxes and noncontrolling interests as follows ($ in thousands):



	Years Ended December 31,
	2,013			2012
United States	$	(38,705.2	)	$	(36,276.9	)
	$	(38,705.2	)	$	(36,276.9	)

The provision (benefit) for income taxes was as follows ($ in thousands):



		Years Ended December 31,
		2013		2012
Current
	US Federal	$	—	$	—
	State and local	—		—
		$	—	$	—
Deferred
	US Federal	$	476.9	$	—
	State and local	303.2		(175.5		)
		$	780.1	$	(175.5	)
Total
	US Federal	$	476.9	$	—
	State and local	303.2		(175.5		)
		$	780.1	$	(175.5	)

The provision (benefit) for income taxes is determined by applying the U.S. Federal statutory rate of 34% to income before income taxes as a result of the following ($ in thousands):



	Years Ended December 31,
	2013			2012
U.S. Federal benefit at statutory rate	(13,159.8		)	(12,334.1		)
State and local benefit net of U.S. federal tax	(3,430.9		)	(2,154.1		)
Permanent non deductible expenses for U.S. taxes	1,798.2			(2,781.4		)
True-up of prior year net operating loss	(91.4		)	321.6
Return to actual	(3,822.9		)	(384.8		)
Foreign earnings not permanently reinvested	—			(1,810.3		)
Effect of change in deferred tax rate	(1,094.8		)	525.7
Valuation allowance for deferred tax assets	20,581.7			18,441.9
Tax provision	$	780.1		$	(175.5	)

Deferred income taxes at December 31, 2013 and 2012 consist of the following ($ in thousands):



	December 31,
	2013			2012
Deferred Tax Assets:
Accumulated net operating losses (tax effected)	$	43,334.8		$	25,727.7
Deferred revenue	10.5			23.1
Contingent accounts payable	13.6			15.2
Share-based compensation	7,971.9			5,466.7
Intangibles	704.6			287.3
Accumulated depreciation	—			348.7
Charitable contributions	414.9			391.8
Bad debt provision	304.3			239.7
Capital loss carry-forward	7,036.8			6,644.5
Deferred tax assets prior to tax credit carryovers	59,791.4			39,144.7

Deferred Tax Liabilities:
Accumulated depreciation	$	(64.8	)	$	—
Intangible and indefinite lived assets	(4,379.2		)	(3,599.1		)
Deferred tax liabilities	(4,444		)	(3,599.1		)
	55,347.4			35,545.6
Valuation reserve	(59,726.6		)	(39,144.7		)
Net deferred tax liability	$	(4,379.2	)	$	(3,599.1	)

In assessing the realizability of deferred tax assets, including the net operating loss carryforwards ("NOLs"), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets. Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.

As of December 31, 2013 and 2012, the Company had approximately $110.6 million and $77.1 million, respectively of Federal NOLs available to offset future taxable income expiring from 2025 through 2033. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s NOLs could be limited in the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible. If a change of ownership did occur there would be an annual limitation on the usage of the Company’s losses which are available through 2032.

As of December 31, 2013, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

+ Details

Discontinued Operations

12 Months Ended

Dec. 31, 2013

Discontinued Operations [Abstract]

Discontinued Operations [Text Block]

Discontinued Operations

Regenerative Medicine - China segment

In 2009, the Company operated its Regenerative Medicine-China business in the People’s Republic of China (“China” or “PRC”) through its subsidiary, a wholly foreign owned entity (“WFOE”) and entered into contractual arrangements with certain variable interest entities (“VIEs”). Foreign companies have commonly used VIE structures to operate in the PRC, and while such structures are not uncommon, recently they have drawn greater scrutiny from the local Chinese business community in the PRC who have urged the PRC State Council to clamp down on these structures. In addition, in December 2011, China’s Ministry of Health announced its intention to more tightly regulate stem cell clinical trials and stem cell therapeutic treatments in the PRC, which has created uncertainty regarding the ultimate regulatory environment in the PRC. Accordingly, the Company took steps to restrict, and ultimately eliminate, its regenerative medicine business in the PRC. As a result of these steps, the Company has discontinued its operations in its Regenerative Medicine-China business. The Company has determined that any liability arising from the activities of the WFOE and the VIEs will likely be limited to the net assets currently held by each entity. As of March 31, 2012, the Company recognized the following loss on exit of the Regenerative Medicine-China business (in thousands):



Cash	$	195.1
Prepaid expenses and other current assets	14.9
Property, plant and equipment, net	1,023.7
Other Assets	330.5
Accounts payable	(177.1		)
Accrued liabilities	(79.2		)
Accumulated comprehensive income	(169.9		)
Loss on exit of segment	$	1,138.0

The operations and cash flows of the Regenerative Medicine - China business were eliminated from ongoing operations as a result of our exit decision, and the Company will not have continuing involvement in this business going forward. The operating results of the Regenerative Medicine – China business for the year ended December 31, 2012, which are included in discontinued operations, were as follows (in thousands):



	Year Ended December 31,
	2012
Revenue	$	52.3
Cost of revenues	(30.6		)
Research and development	(103.3		)
Selling, general, and administrative	(497.3		)
Other income (expense)	(6.8		)
Loss on exit of segment	(1,138.0		)
Loss from discontinued operations	$	(1,723.7	)

Pharmaceutical Manufacturing - China segment

On November 13, 2012, the Company completed the divestiture (the “Erye Sale”) of our 51% interest (the “Erye Interest”) in Suzhou Erye Pharmaceuticals Company Ltd., a Sino-foreign equity joint venture with limited liability organized under the laws of the PRC primarily engaged in the manufacture of generic antibiotics (“Erye”), to Suzhou Erye Economy & Trading Co., Ltd., a limited liability company organized under the laws of the PRC (“EET”), and Highacheive Holdings Limited, a limited liability company organized under the laws of the British Virgin Islands (“Highacheive” and together with EET, each a “Purchaser” and collectively the “Purchasers”). The Erye Sale was consummated pursuant to the terms and conditions of the Equity Purchase Agreement, dated as of June 18, 2012 (as amended, the “Equity Purchase Agreement”), by and among our Company, China Biopharmaceuticals Holdings, Inc., a Delaware corporation and a wholly-owned subsidiary of NeoStem (“CBH”), EET, Highacheive, Fullbright Finance Limited, a limited liability company organized under the laws of the British Virgin Islands (“Fullbright”), and Erye. Pursuant to the Equity Purchase Agreement, the aggregate purchase price paid to the Company by the Purchasers for the Erye Interest consisted of (i) approximately $12.3 million in cash, (ii) the return to the Company of 104,000 shares of NeoStem common stock and (iii) the cancellation of 117,000 options and 64,000 warrants to purchase our common stock. The fair value of the shares was based on the Company's closing price on the date of sale, and was recorded as Treasury Stock in our balance sheet. The fair values of the canceled options and warrants were based on the Black-Scholes values on the date of sale, and were recorded against Additional Paid in Capital in the accompanying balance sheet. The Company recognized the following loss on the date of sale of its 51% interest in Erye (in thousands):



Fair value of consideration received	$	13,397.9
Carrying value of segment non-controlling interest	6,015.0
Carrying value of segment accumulated comprehensive income	4,387.4
	$	23,800.3
Less carrying amount of assets and liabilities sold:
Cash	$	8,457.5
Restricted Cash	2,918.1
Accounts Receivable	6,130.2
Inventories	15,077.7
Prepaid expenses and other current assets	957.8
Property, plant and equipment, net	38,102.0
Other assets	5,946.3
Accounts payable	(9,604.8		)
Accrued liabilities	(2,008.8		)
Bank loans	(15,133.5		)
Notes payable	(6,599.3		)
Other liabilities	(9,166.8		)
Amount due related party	(7,859.7		)
	$	27,216.7

Loss on exit of segment	$	(3,416.4	)

The operations and cash flows of the Pharmaceutical Manufacturing - China business were eliminated from ongoing operations with the sale of the Company's Erye Interest. The operating results of the Pharmaceutical Manufacturing - China business for the year ended December 31, 2012, which are included in discontinued operations, were as follows (in thousands):



	Year Ended December 31,
	2012
Revenue	$	61,703.1
Cost of revenues	(40,245.2		)
Research and development	(1,836.4		)
Selling, general, and administrative	(10,740.0		)
Other expense	(1,045.2		)
Provision for income taxes	(1,794.1		)
Asset impairments	(31,170.1		)
Loss on sale of segment	(3,416.4		)
Loss from discontinued operations	$	(28,544.3	)

- Definition

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 144
-Paragraph 43-48
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2013
Related Party Transactions [Abstract]
Related Party Transactions [Text Block]	On November 13, 2012, we and our subsidiary, CBH, sold our 51% ownership interest in Erye to Fullbright and EET (see Note 15). EET was prior to the sale the holder of the minority 49% ownership interest in Erye, and was a party along with our subsidiary CBH to the Joint Venture Agreement which had governed the ownership of the respective interests in Erye. Fullbright is an affiliate of EET. Mr. Shi Mingsheng (a former member of our Board of Directors, and Chairman of the Board of Erye) and Madam Zhang Jian (the General Manager of Erye, and formerly our Vice President of Pharmaceutical Operations) are the principal equity holders of each of EET and Fullbright. Fullbright assigned all its rights and obligations under the Equity Purchase Agreement (except for its obligations in respect of the return of certain NeoStem securities held by it as part of the purchase price, and its obligations in respect of closing deliverables) to Highacheive Holdings Limited, a limited liability company organized under the laws of the British Virgin Islands and an affiliate of Fullbright (“Highacheive”). As a result of the assignment, the Purchasers of our Erye Interest were EET and Highacheive. In December 2013, the Company modified both the First Mortgage and Second Mortgage with TD Bank, N.A. (see Note 10). Pursuant to the Loan Modifications, Andrew L. Pecora, M.D., Regional Cancer Care Associates LLC (Dr. Pecora’s medical practice), and certain partners in such practice, have been released as guarantors of the Second Mortgage Loan, and NeoStem has become a guarantor of the Loans pursuant to a Guaranty of Payment delivered by NeoStem to the Lender. Dr. Pecora, currently currently serves as a NeoStem director, NeoStem’s Chief Visionary Officer, PCT’s Chief Medical Officer and Amorcyte’s Chief Scientific Officer.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph b
-Article 3A

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph k
-Article 4

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 57
-Paragraph 1-4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2013

Commitments and Contingencies [Abstract]

Commitments and Contingencies [Text Block]

Commitments and Contingencies

Lease Commitments

The Company leases offices, of which certain have escalation clauses and renewal options, and also leases equipment under certain noncancelable operating leases that expire from time to time through 2017. In August 2012, the Company signed a new lease for a larger space at its current executive offices at 420 Lexington Avenue, New York, NY 10170. The new lease is believed to provide sufficient space for the near future. The lease term began in September 2012 and shall extend through June 2015. The base monthly rent, which includes storage space, averages approximately $27,000 per month, with subleases that will aggregate approximately $7,500 per month. This property is used as the Company's corporate headquarters.

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of December 31, 2013 are as follows (in thousands):



Years ended	Operating Leases
2014	$	1,004.0
2015	829.9
2016	671.8
2017	383.4
2018	5.9
Total minimum lease payments	$	2,895.0

Expense incurred under operating leases was approximately $1.1 million and $1.5 million for the year ended December 31, 2013 and 2012, respectively.

Contingencies

Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products. The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2013
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Subsequent Events Common Stock Issuance Pursuant to the Purchase Agreement with Aspire (see Note 12), from January 1, 2014 through March 7, 2014, Aspire has purchased 0.8 million shares of the Company's common stock for an aggregate consideration of approximately $5.6 million. Option and Warrant Exercises Subsequent to December 31, 2013, warrant holders exercised an aggregate of 250,000 warrants at an exercise price of $5.10 per share for gross proceeds of approximately $1.3 million, and option holders exercised an aggregate of 4,800 options at an exercise price of $6.20 per share for gross proceeds of approximately $0.03 million. 2014 Aspire Agreement On March 10, 2014, the Company entered into a Common Stock Purchase Agreement with Aspire, whereby Aspire is committed to purchase up to an aggregate of $30.0 million of shares of NeoStem common stock over a 24-month term.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2013

Revenue Recognition [Abstract]

Property, Plant and Equipment, Policy [Policy Text Block]



Building and improvements	25-30 years
Machinery and equipment	8-12 years
Lab equipment	5-7 years
Furniture and fixtures	5-12 years
Software	3-5 years
Leasehold improvements	Life of lease

Revenue Recognition, Policy [Policy Text Block]

Treasury Stock

Revenue Recognition

Clinical Services: The Company recognizes revenue for its (i) cell process development and (ii) cell manufacturing services based on the terms of individual contracts.


•	persuasive evidence of an arrangement exists;


•	delivery has occurred or the services have been rendered;


•	the fee is fixed or determinable; and


•	collectability is probable.

- Definition

Disclosure of accounting policy for property, plant and equipment which may include the basis of such assets, depreciation methods used and estimated useful lives, the entity's capitalization policy, including its accounting treatment for costs incurred for repairs and maintenance activities, whether such asset balances include capitalized interest and the method by which such is calculated, how disposals of such assets are accounted for and how impairment of such assets is assessed and recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2155824

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 34
-Paragraph 8, 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section C
-Paragraph 5
-Chapter 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 5
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 22
-Paragraph 12, 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 144
-Paragraph 7
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 13
-Subparagraph a
-Article 5

+ Details

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

The Business (Tables)

12 Months Ended

Dec. 31, 2013

The Business [Abstract]

Subsidiary [Table Text Block]

segment through November 13, 2012, representing the date which the segment was sold (see Note 15). These former segments are reported in discontinued operations.



Entity	Percentage of Ownership	Location
NeoStem, Inc.	Parent Company	United States of America
NeoStem Therapies, Inc.	100%	United States of America
Stem Cell Technologies, Inc.	100%	United States of America
Amorcyte, LLC	100%	United States of America
Progenitor Cell Therapy, LLC (PCT)	100%	United States of America
NeoStem Family Storage, LLC	100%	United States of America
Athelos Corporation (1)	88.5%	United States of America
PCT Allendale, LLC	100%	United States of America

Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Property, Plant and Equipment [Table Text Block]



Building and improvements	25-30 years
Machinery and equipment	8-12 years
Lab equipment	5-7 years
Furniture and fixtures	5-12 years
Software	3-5 years
Leasehold improvements	Life of lease

Property, plant, and equipment consisted of the following (in thousands):



	December 31,
	2013			2012
Building and improvements	$	11,229.9		$	9,897.8
Machinery and equipment	58.2			39.5
Lab equipment	2,743.7			1,800.6
Furniture and fixtures	958.0			683.7
Software	203.1			99.5
Leasehold improvements	674.1			654.5
Property, plant and equipment, gross	15,867.0			13,175.6
Accumulated depreciation	(3,022.8		)	(2,022.5		)
Property, plant and equipment, net	$	12,844.2		$	11,153.1

Property, Plant & Equipment (Tables)

12 Months Ended

Dec. 31, 2013

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]



Building and improvements	25-30 years
Machinery and equipment	8-12 years
Lab equipment	5-7 years
Furniture and fixtures	5-12 years
Software	3-5 years
Leasehold improvements	Life of lease

Property, plant, and equipment consisted of the following (in thousands):



	December 31,
	2013			2012
Building and improvements	$	11,229.9		$	9,897.8
Machinery and equipment	58.2			39.5
Lab equipment	2,743.7			1,800.6
Furniture and fixtures	958.0			683.7
Software	203.1			99.5
Leasehold improvements	674.1			654.5
Property, plant and equipment, gross	15,867.0			13,175.6
Accumulated depreciation	(3,022.8		)	(2,022.5		)
Property, plant and equipment, net	$	12,844.2		$	11,153.1

Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2013

Loss Per Share [Abstract]

ScheduleOfDilutiveSecuritiesExcludedFromComputationOfEarningsPerShare [Table Text Block]

At December 31, 2013 and 2012, the Company excluded the following potentially dilutive securities:



	December 31,
	2013	2012
Stock Options	2,932,191	2,168,668
Warrants	4,898,266	5,528,761
Restricted Shares	78,500	34,250

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2013

Fair Value Measurements [Abstract]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis, Valuation Techniques [Table Text Block]

The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2013, and December 31, 2012 (in thousands):



	December 31, 2013
	Fair Value Measurements Using Fair Value Hierarchy
	Level 1		Level 2		Level 3
Warrant derivative liabilities	$	—	$	—	$	23.2
Contingent consideration	—		—		9,450.0



	December 31, 2012
	Fair Value Measurements Using Fair Value Hierarchy
	Level 1		Level 2		Level 3
Warrant derivative liabilities	$	—	$	—	$	101.2
Contingent consideration	—		—		7,550.0

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the year ended December 31, 2013 by type of instrument (in thousands):



	Year Ended
	December 31, 2013
	Warrants			Contingent Consideration
Beginning liability balance	$	101.2		$	7,550.0
Change in fair value recorded in earnings	(78.0		)	1,900.0
Ending liability balance	$	23.2		$	9,450.0

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References + Details

Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2013

Goodwill and Other Intangible Assets [Abstract]

Schedule of Finite-Lived Intangible Assets by Major Class [Table Text Block]

s of December 31, 2013 and December 31, 2012 consisted of the following (in thousands):



		December 31, 2013							December 31, 2012
	Useful Life	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer list	10 years	$	1,000.0	$	(295.1	)	$	704.9	$	1,000.0	$	(195.1	)	$	804.9
Manufacturing technology	10 years	3,900.0		(1,150.9		)	2,749.1		3,900.0		(760.9		)	3,139.1
Tradename	10 years	800.0		(236.1		)	563.9		800.0		(156.1		)	643.9
In process R&D	Indefinite	9,400.0		—			9,400.0		9,400.0		—			9,400.0
VSEL patent rights	19 years	669.0		(211.3		)	457.7		669.0		(176.1		)	492.9
Total Intangible Assets		$	15,769.0	$	(1,893.4	)	$	13,875.6	$	15,769.0	$	(1,288.2	)	$	14,480.8

Schedule of Amortization Expense [Table Text Block]

Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):



	Year Ended December 31,
	2013		2012
Cost of revenue	$	390.0	$	390.0
Research and development	35.2		35.2
Selling, general and administrative	180.0		180.0
Total	$	605.2	$	605.2

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Estimated intangible amortization expense on an annual basis for the succeeding five years is as follow (in thousands):



2014	$	605.2
2015	605.2
2016	605.2
2017	605.2
2018	605.2
Thereafter	10,849.6
	$	13,875.6

Accrued Liabilities Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2013

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Accrued liabilities were as follow (in thousands):



	December 31,
	2013		2012
Salaries, employee benefits and related taxes	$	2,325.8	$	1,597.2
Professional fees	544.8		606.6
License fees	500.0		—
Other	647.4		81.0
	$	4,018.0	$	2,284.8

Shareholders' Equity (Tables)

12 Months Ended

Dec. 31, 2013

Shareholders’ Equity [Abstract]

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]

The number of remaining shares authorized to be issued under the various equity plans are as follows:



	2003 Equity Plan		2009 Equity Plan
Shares Authorized for Issuance	250,000		5,995,000
Outstanding Stock Options	(136,480	)	(2,795,711	)
Exercised Stock Options	(9,250	)	(31,869	)
Restricted stock or equity grants issued under Equity Plans	(88,993	)	(595,852	)
Shares Expired	(15,277	)	—
Total common shares remaining to be issued under the Equity Plans	—		2,571,568

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes the activity for stock options and warrants for the years ended December 31, 2013 and December 31, 2012:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2012	2,168,668		$	12.85	6.8	$	1,658.1	5,528,761		$	15.65	3.6	$	1,300.0

Changes during the Year:
Granted	959,167		$	7.01				86,250		$	6.66
Exercised	(31,369	)	$	4.80				(563,166	)	$	5.38
Forfeited	(89,412	)	$	5.54				(17,500	)	$	14.20
Expired	(74,863	)	$	15.40				(136,079	)	$	20.15
Outstanding at December 31, 2013	2,932,191		$	11.19	6.8	$	1,658.1	4,898,266		$	16.50	2.6	$	1,811.0
Vested at December 31, 2013 or expected to vest in the future	2,816,138		$	11.36	6.7	$	1,604.0	4,884,957		$	16.35	2.6	$	1,811.0
Exercisable at December 31, 2013	2,231,869		$	12.14	6.4	$	1,283.3	4,780,658		$	15.41	2.6	$	1,811.0

The following table summarizes the components of share-based compensation expense for the year ended December 31, 2013 and 2012 ($ in thousands):



	Year Ended December 31,
	2013		2012
Cost of goods sold	$	314.0	$	195.0
Research and development	822.2		432.9
Selling, general and administrative	5,702.5		6,084.6
Total share-based compensation expense	$	6,838.7	$	6,712.5

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

During the year ended December 31, 2013 and 2012, the Company issued warrants for services as follows ($ in thousands, except share data):



	Year Ended December 31,
	2013		2012
Number of Common Stock Purchase Warrants Issued	40,407		41,969
Value of Common Stock Purchase Warrants Issued	$	149.9	$	172.2

Restricted Stock [Table Text Block]

During the year ended December 31, 2013 and 2012, the Company issued restricted stock for services as follows ($ in thousands, except share data):



	Year Ended December 31,
	2013		2012
Number of Restricted Stock Issued	514,700		229,553
Value of Restricted Stock Issued	$	3,360.0	$	1,325.1

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Share-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2013

Share-based Compensation [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes the activity for stock options and warrants for the years ended December 31, 2013 and December 31, 2012:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2012	2,168,668		$	12.85	6.8	$	1,658.1	5,528,761		$	15.65	3.6	$	1,300.0

Changes during the Year:
Granted	959,167		$	7.01				86,250		$	6.66
Exercised	(31,369	)	$	4.80				(563,166	)	$	5.38
Forfeited	(89,412	)	$	5.54				(17,500	)	$	14.20
Expired	(74,863	)	$	15.40				(136,079	)	$	20.15
Outstanding at December 31, 2013	2,932,191		$	11.19	6.8	$	1,658.1	4,898,266		$	16.50	2.6	$	1,811.0
Vested at December 31, 2013 or expected to vest in the future	2,816,138		$	11.36	6.7	$	1,604.0	4,884,957		$	16.35	2.6	$	1,811.0
Exercisable at December 31, 2013	2,231,869		$	12.14	6.4	$	1,283.3	4,780,658		$	15.41	2.6	$	1,811.0

The following table summarizes the components of share-based compensation expense for the year ended December 31, 2013 and 2012 ($ in thousands):



	Year Ended December 31,
	2013		2012
Cost of goods sold	$	314.0	$	195.0
Research and development	822.2		432.9
Selling, general and administrative	5,702.5		6,084.6
Total share-based compensation expense	$	6,838.7	$	6,712.5

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]



	Stock Options		Warrants		Restricted Stock
Unrecognized compensation cost	$	2,422.2	$	55.6	$	335.6
Expected weighted-average period in years of compensation cost to be recognized	3.51		1.54		0.38

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]

Total fair value of shares vested and the weighted average estimated fair values of shares grant for the year ended December 31, 2013 and 2012 were as follows ($ in thousands):



	Stock Options				Warrants
	Year Ended December 31,				Year Ended December 31,
	2013		2012		2013		2012
Total fair value of shares vested	$	3,375.7	$	5,408.0	$	129.0	$	171.6
Weighted average estimated fair value of shares granted	4.29		3.63		3.71		4.10

Schedule of Range of Fair Value of Stock Options and Warrants [Table Text Block]

The range of assumptions made in calculating the fair values of stock options and warrants was as follow:



	Stock Options		Warrants
	Year Ended December 31,		Year Ended December 31,
	2013	2012	2013	2012
Expected term - minimum (in years)	1	2	2	2
Expected term - maximum (in years)	10	10	5	5
Expected volatility - minimum	61%	73%	73%	76%
Expected volatility - maximum	79%	84%	79%	83%
Expected dividend yield	—	—	—	—
Risk-free interest rate - minimum	0.13%	0.28%	0.32%	0.27%
Risk-free interest rate - maximum	2.67%	1.99%	1.73%	0.88%

- Definition

Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan. Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.

+ References + Details

Income Taxes income taxes (Tables)

12 Months Ended

Dec. 31, 2013

Income Taxes [Abstract]

Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]



	Years Ended December 31,
	2013			2012
U.S. Federal benefit at statutory rate	(13,159.8		)	(12,334.1		)
State and local benefit net of U.S. federal tax	(3,430.9		)	(2,154.1		)
Permanent non deductible expenses for U.S. taxes	1,798.2			(2,781.4		)
True-up of prior year net operating loss	(91.4		)	321.6
Return to actual	(3,822.9		)	(384.8		)
Foreign earnings not permanently reinvested	—			(1,810.3		)
Effect of change in deferred tax rate	(1,094.8		)	525.7
Valuation allowance for deferred tax assets	20,581.7			18,441.9
Tax provision	$	780.1		$	(175.5	)

Deferred income taxes at December 31, 2013 and 2012 consist of the following ($ in thousands):

Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]



	Years Ended December 31,
	2,013			2012
United States	$	(38,705.2	)	$	(36,276.9	)
	$	(38,705.2	)	$	(36,276.9	)

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]



		Years Ended December 31,
		2013		2012
Current
	US Federal	$	—	$	—
	State and local	—		—
		$	—	$	—
Deferred
	US Federal	$	476.9	$	—
	State and local	303.2		(175.5		)
		$	780.1	$	(175.5	)
Total
	US Federal	$	476.9	$	—
	State and local	303.2		(175.5		)
		$	780.1	$	(175.5	)

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]



	December 31,
	2013			2012
Deferred Tax Assets:
Accumulated net operating losses (tax effected)	$	43,334.8		$	25,727.7
Deferred revenue	10.5			23.1
Contingent accounts payable	13.6			15.2
Share-based compensation	7,971.9			5,466.7
Intangibles	704.6			287.3
Accumulated depreciation	—			348.7
Charitable contributions	414.9			391.8
Bad debt provision	304.3			239.7
Capital loss carry-forward	7,036.8			6,644.5
Deferred tax assets prior to tax credit carryovers	59,791.4			39,144.7

Deferred Tax Liabilities:
Accumulated depreciation	$	(64.8	)	$	—
Intangible and indefinite lived assets	(4,379.2		)	(3,599.1		)
Deferred tax liabilities	(4,444		)	(3,599.1		)
	55,347.4			35,545.6
Valuation reserve	(59,726.6		)	(39,144.7		)
Net deferred tax liability	$	(4,379.2	)	$	(3,599.1	)

Discontinued Operations (Tables)

12 Months Ended

Dec. 31, 2013

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]

Stock in our balance sheet. The fair values of the canceled options and warrants were based on the Black-Scholes values on the date of sale, and were recorded against Additional Paid in Capital in the accompanying balance sheet. The Company recognized the following loss on the date of sale of its 51% interest in Erye (in thousands):



Fair value of consideration received	$	13,397.9
Carrying value of segment non-controlling interest	6,015.0
Carrying value of segment accumulated comprehensive income	4,387.4
	$	23,800.3
Less carrying amount of assets and liabilities sold:
Cash	$	8,457.5
Restricted Cash	2,918.1
Accounts Receivable	6,130.2
Inventories	15,077.7
Prepaid expenses and other current assets	957.8
Property, plant and equipment, net	38,102.0
Other assets	5,946.3
Accounts payable	(9,604.8		)
Accrued liabilities	(2,008.8		)
Bank loans	(15,133.5		)
Notes payable	(6,599.3		)
Other liabilities	(9,166.8		)
Amount due related party	(7,859.7		)
	$	27,216.7

Loss on exit of segment	$	(3,416.4	)

Balance Sheet [Member] | Regenerative Medicine - China segment [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]

As of March 31, 2012, the Company recognized the following loss on exit of the Regenerative Medicine-China business (in thousands):



Cash	$	195.1
Prepaid expenses and other current assets	14.9
Property, plant and equipment, net	1,023.7
Other Assets	330.5
Accounts payable	(177.1		)
Accrued liabilities	(79.2		)
Accumulated comprehensive income	(169.9		)
Loss on exit of segment	$	1,138.0

Income Statement [Member] | Regenerative Medicine - China segment [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]



	Year Ended December 31,
	2012
Revenue	$	52.3
Cost of revenues	(30.6		)
Research and development	(103.3		)
Selling, general, and administrative	(497.3		)
Other income (expense)	(6.8		)
Loss on exit of segment	(1,138.0		)
Loss from discontinued operations	$	(1,723.7	)

Income Statement [Member] | Pharmaceutical Manufacturing - China business [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]



	Year Ended December 31,
	2012
Revenue	$	61,703.1
Cost of revenues	(40,245.2		)
Research and development	(1,836.4		)
Selling, general, and administrative	(10,740.0		)
Other expense	(1,045.2		)
Provision for income taxes	(1,794.1		)
Asset impairments	(31,170.1		)
Loss on sale of segment	(3,416.4		)
Loss from discontinued operations	$	(28,544.3	)

- Definition

Tabular disclosure of disposal groups, which may include the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the classification and carrying value of the assets and liabilities comprising the disposal group, and the segment in which the disposal group was reported. Also may include the amount of adjustments to amounts previously reported in discontinued operations such as resolution of contingencies arising from the disposal transaction or the operations of the component prior to disposal.

+ References + Details

Discontinued Operations Fair value of discontinued operations (Tables)

12 Months Ended

Dec. 31, 2013

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]



Fair value of consideration received	$	13,397.9
Carrying value of segment non-controlling interest	6,015.0
Carrying value of segment accumulated comprehensive income	4,387.4
	$	23,800.3
Less carrying amount of assets and liabilities sold:
Cash	$	8,457.5
Restricted Cash	2,918.1
Accounts Receivable	6,130.2
Inventories	15,077.7
Prepaid expenses and other current assets	957.8
Property, plant and equipment, net	38,102.0
Other assets	5,946.3
Accounts payable	(9,604.8		)
Accrued liabilities	(2,008.8		)
Bank loans	(15,133.5		)
Notes payable	(6,599.3		)
Other liabilities	(9,166.8		)
Amount due related party	(7,859.7		)
	$	27,216.7

Loss on exit of segment	$	(3,416.4	)

- Definition

+ References + Details

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2013

Commitments and Contingencies [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of December 31, 2013 are as follows (in thousands):



Years ended	Operating Leases
2014	$	1,004.0
2015	829.9
2016	671.8
2017	383.4
2018	5.9
Total minimum lease payments	$	2,895.0

Equity Plan (Tables)

12 Months Ended

Dec. 31, 2013

Statement of Stockholders' Equity [Abstract]

Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]

The number of remaining shares authorized to be issued under the various equity plans are as follows:



	2003 Equity Plan		2009 Equity Plan
Shares Authorized for Issuance	250,000		5,995,000
Outstanding Stock Options	(136,480	)	(2,795,711	)
Exercised Stock Options	(9,250	)	(31,869	)
Restricted stock or equity grants issued under Equity Plans	(88,993	)	(595,852	)
Shares Expired	(15,277	)	—
Total common shares remaining to be issued under the Equity Plans	—		2,571,568

The Business (Details) - segment	Jun. 19, 2012	Jun. 18, 2012
The Company [Line Items]
Number of Reporting Segments	1	3

The Business Principal of consolidation (Details) $ in Millions	12 Months Ended
	Dec. 31, 2013 USD ($)
NeoStem, Inc. [Member]
Schedule of Subisidiary [Line Items]
Minority Interest Ownership Percentage By Parent [String]	Parent Company
NeoStem, Inc. [Member] \| Location [Member]
Schedule of Subisidiary [Line Items]
The Business [Text Block]	United States of America
NeoStem Therapies, Inc [Member] \| Location [Member]
Schedule of Subisidiary [Line Items]
The Business [Text Block]	United States of America
NeoStem Therapies, Inc [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Stem Cell Technologies, Inc [Member] \| Location [Member]
Schedule of Subisidiary [Line Items]
The Business [Text Block]	United States of America
Stem Cell Technologies, Inc [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Amorcyte, LLC [Member] \| Location [Member]
Schedule of Subisidiary [Line Items]
The Business [Text Block]	United States of America
Amorcyte, LLC [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
China Biopharmaceuticals Holdings, Inc. [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	100.00%
Suzhou Erye Pharmaceuticals Company Ltd. [Member] \| CHINA
Schedule of Subisidiary [Line Items]
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	51.00%
Progenitor Cell Therapy, LLC [Member] \| Location [Member]
Schedule of Subisidiary [Line Items]
The Business [Text Block]	United States of America
Progenitor Cell Therapy, LLC [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
NeoStem Family Storage, LLC [Member]
Schedule of Subisidiary [Line Items]
Minority Interest Ownership Percentage By Parent [String]	1
NeoStem Family Storage, LLC [Member] \| Location [Member]
Schedule of Subisidiary [Line Items]
The Business [Text Block]	United States of America
NeoStem Family Storage, LLC [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	100.00%
Athelos Corporation [Member]
Schedule of Subisidiary [Line Items]
Minority Interest Ownership Percentage By Parent [String]	0.885
Athelos Corporation [Member] \| Location [Member]
Schedule of Subisidiary [Line Items]
The Business [Text Block]	United States of America
Athelos Corporation [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	80.10%
PCT Allendale, LLC [Member]
Schedule of Subisidiary [Line Items]
Minority Interest Ownership Percentage By Parent [String]	1
PCT Allendale, LLC [Member] \| Location [Member]
Schedule of Subisidiary [Line Items]
The Business [Text Block]	United States of America
PCT Allendale, LLC [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	100.00%
Noncontrolling Interest [Member]
Schedule of Subisidiary [Line Items]
Change in Ownership in Subsidiary	$ 0.3

Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Clinical Services Reimbursement	$ 2.1	$ 3.5
Revene Recognition Period for Cryoperservation Process	24 hours
Building and Building Improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	P25Y
Building and Building Improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	P30Y
Machinery and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	P8Y
Machinery and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	P12Y
Lab Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	P5Y
Lab Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	P7Y
Furniture and Fixtures [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	P5Y
Furniture and Fixtures [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	P12Y
Software [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	P3Y
Software [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	P5Y
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	life of lease

Cash and Cash Equivalents (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Restricted Cash and Cash Equivalents Items [Line Items]
Cash and cash equivalents	$ 46,133,759	$ 13,737,452
Cash, FDIC Insured Amount	$ 700,000	$ 800,000

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7
-Footnote 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 8, 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Inventories (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Schedule of Inventory [Line Items]
Inventory	$ 1,270,223	$ 1,113,025
Multiple Stage Contracts [Member]
Schedule of Inventory [Line Items]
Deferred Revenue	$ 1,500,000	$ 1,200,000

Property, Plant & Equipment (Details) - USD ($)	12 Months Ended
Property, Plant & Equipment (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Buildings and Improvements, Gross	$ 11,229,900	$ 9,897,800
Machinery and Equipment, Gross	58,200	39,500
Property, Plant and Equipment, Other, Gross	2,743,700	1,800,600
Furniture and Fixtures, Gross	958,000	683,700
Capitalized Computer Software, Gross	203,100	99,500
Leasehold Improvements, Gross	674,100	654,500
Property, Plant and Equipment, Gross	15,867,000	13,175,600
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	3,022,800	2,022,500
Property, plant and equipment, net	12,844,216	11,153,143
Depreciation, Depletion and Amortization	1,000,000	1,000,000
Property, Plant and Equipment, Other Types [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	$ 12,844,200	$ 11,153,100

Loss Per Share (Details) - shares	12 Months Ended
Loss Per Share (Details) - shares	Dec. 31, 2013	Dec. 31, 2012
Stock Options [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	2,932,191	2,168,668
Warrant [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	4,898,266	5,528,761
Restricted Stock [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	78,500	34,250

Fair Value Measurements (Details)	12 Months Ended
Fair Value Measurements (Details)	Dec. 31, 2013
contingent cosideration [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value Inputs Discount Rate	18.00%

Fair Value Measurements Fair value hierarchy the Company’s financial assets and liabilities (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition-related contingent consideration	$ 9,450,000	$ 7,550,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Derivative Liabilities	0	0
Contingent Consideration Classified As Equity Fair Value Disclosure	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Derivative Liabilities	0	0
Contingent Consideration Classified As Equity Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Derivative Liabilities	23,200	101,200
Contingent Consideration Classified As Equity Fair Value Disclosure	$ 9,450,000	$ 7,550,000

Fair Value Measurements Financial instruments with significant Level 3 inputs (Details) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Derivative Financial Instruments, Liabilities [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Begining liability balance	$ 0	$ 391,700
Change in fair value recorded in earnings		(391,700)
Begining liability balance		0
Warrant [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Begining liability balance	101,200	82,700
Change in fair value recorded in earnings	(78,000)	18,500
Begining liability balance	23,200	101,200
contingent cosideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Begining liability balance	7,550,000	3,130,000
Change in fair value recorded in earnings	1,900,000	4,420,000
Begining liability balance	$ 9,450,000	$ 7,550,000

Goodwill and Other Intangible Assets Goodwill (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Goodwill [Line Items]
Future Amortization Expense, Year One	$ 605,200
Future Amortization Expense, Year Two	605,200
Future Amortization Expense, Year Three	605,200
Future Amortization Expense, Year Four	605,200
Future Amortization Expense, Year Five	605,200
Future Amortization Expense, after Year Five	10,849,600
Finite-Lived Intangible Assets, Net	$ 13,875,600	$ 14,480,800

Goodwill and Other Intangible Assets Intangible Assets and Related Accumulated Amortization (Details) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 15,769,000	$ 15,769,000
Finite-Lived Intangible Assets, Accumulated Amortization	(1,893,400)	(1,288,200)
Finite-Lived Intangible Assets, Net	13,875,600	14,480,800
Customer Lists [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	1,000,000	1,000,000
Finite-Lived Intangible Assets, Accumulated Amortization	(295,100)	(195,100)
Finite-Lived Intangible Assets, Net	$ 704,900	804,900
Finite-Lived Intangible Assets, Useful Life	10 years
Manufacturing Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 3,900,000	3,900,000
Finite-Lived Intangible Assets, Accumulated Amortization	(1,150,900)	(760,900)
Finite-Lived Intangible Assets, Net	$ 2,749,100	3,139,100
Finite-Lived Intangible Assets, Useful Life	10 years
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 800,000	800,000
Finite-Lived Intangible Assets, Accumulated Amortization	(236,100)	(156,100)
Finite-Lived Intangible Assets, Net	$ 563,900	643,900
Finite-Lived Intangible Assets, Useful Life	10 years
In Process R&D [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 9,400,000	9,400,000
Finite-Lived Intangible Assets, Accumulated Amortization	0	0
Finite-Lived Intangible Assets, Net	$ 9,400,000	9,400,000
Finite Lived Intangible Assets, Useful Life [String]	Indefinite
VSEL Patent Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 669,000	669,000
Finite-Lived Intangible Assets, Accumulated Amortization	(211,300)	(176,100)
Finite-Lived Intangible Assets, Net	$ 457,700	$ 492,900
Finite-Lived Intangible Assets, Useful Life	19 years

Goodwill and Other Intangible Assets Intangible Amortization Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Intangible Asset Amortization Expense By Category [Line Items]
Amortization of Intangible Assets	$ 605,200	$ 605,200
Cost of Sales [Member]
Intangible Asset Amortization Expense By Category [Line Items]
Amortization of Intangible Assets	390,000	390,000
General and Administrative Expense [Member]
Intangible Asset Amortization Expense By Category [Line Items]
Amortization of Intangible Assets	180,000	180,000
Research and Development Expense [Member]
Intangible Asset Amortization Expense By Category [Line Items]
Amortization of Intangible Assets	$ 35,200	$ 35,200

Accrued Liabilities Accrued Liabilities (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Accrued Liabilities [Abstract]
Employee-related Liabilities	$ 2,325.8	$ 1,597.2
Accrued Professional Fees	544.8	606.6
Accrued Royalties, Current	500.0	0.0
Other Accrued Liabilities	647.4	81.0
Accrued Liabilities	$ 4,018.0	$ 2,284.8

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

Debt (Details) - USD ($)			12 Months Ended
Debt (Details) - USD ($)	Dec. 06, 2010	Oct. 31, 2007	Dec. 31, 2013	Dec. 31, 2012
Debt Instrument [Line Items]
Notes Payable			$ 900,000	$ 400,000
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Subordinated Notes to Finance Leveraged Buyout		$ 3,100,000
Purchase of condominium units		$ 3,800,000
Debt Instrument, Frequency of Periodic Payment		monthly payments
Debt Instrument, Periodic Payment, Interest			5.00%
Mortgage Loans on Real Estate, Carrying Amount of Mortgages			$ 2,500,000	2,600,000
PCT Allendale, LLC [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment			20,766
Mortgage Loan Repayble Amount within 12 months				126,700
PCT Allendale, LLC [Member] \| Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Subordinated Notes to Finance Leveraged Buyout	$ 1,000,000
Debt Instrument, Period of Loan	124 months
Debt Instrument, Periodic Payment, Interest	6.00%
Debt Instrument, Period of Fixed Interest Rate	64 months
Mortgage Loans on Real Estate, Carrying Amount of Mortgages			763,000	$ 844,300
Mortgage Loan Repayble Amount within 12 months			$ 86,400

Debt Debt Disclosure (Details) - USD ($)			12 Months Ended
Debt Debt Disclosure (Details) - USD ($)	Dec. 06, 2010	Oct. 31, 2007	Dec. 31, 2013	Dec. 31, 2012
Debt Instrument [Line Items]
Notes Payable			$ 900,000	$ 400,000
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period			5.00%
Subordinated Notes to Finance Leveraged Buyout		$ 3,100,000
Mortgage Loans on Real Estate, Carrying Amount of Mortgages			$ 2,500,000	2,600,000
PCT Allendale, LLC [Member] \| Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate During Period	6.00%
Subordinated Notes to Finance Leveraged Buyout	$ 1,000,000
Mortgage Loans on Real Estate, Carrying Amount of Mortgages			$ 763,000	$ 844,300

Preferred Stock Convertible Redeemable Series E Preferred Stock (Details) - USD ($)		12 Months Ended
	Nov. 19, 2010	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2013	Oct. 25, 2012	Sep. 30, 2012	Dec. 31, 2011
Class of Stock [Line Items]
Preferred Offering Units	10,582,011
Preferred stock, par value	$ 0.01	$ 0.01	$ 0.01
Sale of Stock, Price Per Share	$ 0.945			$ 5.60
Net proceeds from issuance of capital stock		$ 58,736,165	$ 16,428,827
Preferred Stock, Shares Outstanding		10,000	10,000		2,351,558
Common stock issued in payment of dividends for the Convertible Redeemable Series E 7% Preferred Stock		$ 3,400,000
Proceeds from (Repurchase of) Redeemable Preferred Stock			$ 2,500,000
Payments of Dividends, Preferred Stock and Preference Stock		3,100,000
Payments for Repurchase of Redeemable Preferred Stock		200,000
Increase (Decrease) in Interest Payable, Net		$ 36,000
Series E Seven Percent Senior Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Percent of Preferred Shares Required to be Redeemed Monthly		3.7037%
Number of Shares of Preferred Stock Included in Preferred Offering Unit	1
Preferred Stock, Dividend Rate, Percentage	7.00%
Warrant to purchase 0.25 of a share of Common Stock [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	0.25
Stock and Warrants Issued During Period, Shares, Preferred Stock and Warrants	132,249					222,446
Warrant to purchase 0.0155 of a share of Common Stock [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	0.0155
Stock and Warrants Issued During Period, Shares, Preferred Stock and Warrants	16,442
Preferred Offering Unit [Member]
Class of Stock [Line Items]
Net proceeds from issuance of capital stock	$ 10,000,000
Net Proceeds from Issuance or Sale of Equity	$ 8,900,000
Warrant [Member]
Class of Stock [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value		$ 23,200	$ 101,200				$ 82,700

Shareholders' Equity (Details) - USD ($)		3 Months Ended	12 Months Ended
Shareholders' Equity (Details) - USD ($)	Sep. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Mar. 11, 2014	Oct. 31, 2013	Jun. 30, 2013	Oct. 10, 2012	Oct. 14, 2011	Sep. 30, 2011	Sep. 28, 2011	Jan. 18, 2011	Nov. 19, 2010	Jun. 02, 2010	Oct. 29, 2009	May 09, 2009
Class of Stock [Line Items]
Common Stock, Shares Authorized			500,000,000	500,000,000
weighted average estimated fair value of restricted stock		$ 5.77	$ 6.53
Stock Issued During Period, Shares, Restricted Stock Award, Gross			514,700	229,553
Common Stock, Par or Stated Value Per Share			$ 0.001	$ 0.001	$ 0.001
Proceeds from Warrant Exercises			$ 3,028,241	$ 6,604,418
Warrant inducements			$ 0	$ (1,012,819)
Warrant inducements			40,407	41,969
Sale of Stock, Price Per Share							$ 5.60						$ 0.945
Stock Issued During Period, Value, Restricted Stock Award, Gross			$ 3,360,000	$ 1,325,100
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues			9,712,724	3,573,229
Warrant inducements			0	145,895
Warrant holder A [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			600,000
Proceeds from Issuance of Warrants			$ 3,000,000
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Committment Value Under Purchase Agreement											$ 20,000,000
Term Of Agreement In Months											24
Discount Applied To Weighted Average Price											5.00%
Shares, Issued										99,010
Private Placement [Member]
Class of Stock [Line Items]
Warrant inducements	161,290
Investment Warrants, Exercise Price	$ 6.00
Non US Equity Plan [Member] \| Employee Stock Option [Member]
Class of Stock [Line Items]
Common Stock, Shares Authorized								570,000	570,000					870,000	470,000
2009 Equity Plan [Member] \| Employee Stock Option [Member]
Class of Stock [Line Items]
Common Stock, Shares Authorized						2,600,000		450,000	2,375,000			1,775,000		1,375,000	975,000	380,000

Shareholders' Equity Components of share-based compensation expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Oct. 31, 2013	Jun. 30, 2013	Oct. 10, 2012	Oct. 14, 2011	Jan. 18, 2011	Nov. 19, 2010	Jun. 02, 2010	Oct. 29, 2009	May 09, 2009
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	(4,780,658)
Common Stock, Shares Authorized	500,000,000	500,000,000
Sale of Stock, Price Per Share				$ 5.60				$ 0.945
Share-based Compensation Expense	$ 6,838,700
Common Stock, Shares, Outstanding	27,196,537	16,375,365
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Expense	$ 314,000	$ 195,000
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Expense	822,200	432,900
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Expense	$ 5,702,500	$ 6,084,600
Employee Stock Option [Member] \| 2009 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Shares Authorized			2,600,000		450,000	2,375,000	1,775,000		1,375,000	975,000	380,000
Employee Stock Option [Member] \| Non US Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Shares Authorized					570,000	570,000			870,000	470,000
2009 Equity Plan [Member] \| US Equity Plan [Member] \| Employee Stock Option [Member] \| 2009 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	(31,869)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	(595,852)
Common Stock, Shares Authorized	5,995,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	(2,795,711)
Common Stock, Shares, Outstanding	2,571,568
2003 Equity Plan [Member] \| US Equity Plan [Member] \| Employee Stock Option [Member] \| 2003 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	(9,250)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	(88,993)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	(15,277)
Common Stock, Shares Authorized	250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	(136,480)
Common Stock, Shares, Outstanding	0

Shareholders' Equity Activity for stock options and warrants (Details)	12 Months Ended
	Dec. 31, 2013 USD ($) $ / shares $ / warrant shares	Dec. 31, 2012 USD ($) $ / shares $ / warrant shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value \| $	$ 1,658,100
Common Stock, Shares, Outstanding	27,196,537	16,375,365
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value \| $	$ 1,283,300	$ 1,658,100
Common Stock Warrants, Shares		5,528,761
Weighted Average Exercise Price, Warrants Outstanding \| $ / warrant	16.50	15.65
Weighted Average Remaining Contractual Term warrant outstanding	2 years 7 months 17 days
Weighted Average Remaining Contractual Term, Warrants Outstanding		3 years 7 months 6 days
Aggregate Intrinsic Value, Warrants Outstanding \| $	$ 1,811,000	$ 1,300,000
Warrant inducements	40,407	41,969
Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Outstanding [Roll Forward]
Warrants Granted	86,250
Weighted Average Exercise Price, Warrants Granted \| $ / shares	$ 6.66
Warrants Exercised	(563,166)
Weighted Average Exercise Price, Warrants Exercised \| $ / shares	$ 5.38
Warrants Expired	(17,500)
Weighted Average Exercise Price, Warrants Expired \| $ / shares	$ 14.20
Warrants Canceled	(136,079)
Weighted Average Exercise Price, Warrants Canceled \| $ / shares	$ 20.15
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value \| $	$ 1,604,000
shares, vested and expected to vest	4,884,957
Weighted Average Exercise Price, Warrants vested & expected to vest \| $ / warrant	16.35
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	4,780,658
Weighted Average Exercise Price, Warrants Exercisable \| $ / warrant	15.41
weighted Average Remaining Contractual Term, warrants vested	2 years 7 months 2 days
Aggregate Intrinsic Value, Warrants vested and expected to vest \| $	$ 1,811,000
Aggregate Intrinsic Value, Warrants vested \| $	$ 1,811,000
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Outstanding [Roll Forward]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price \| $ / shares	$ 3.71	$ 4.10
US Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 11.19	$ 12.85
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	6 years 9 months 22 days	6 years 9 months 11 days
Common Stock, Shares, Outstanding	4,898,266
Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest	2 years 7 months 13 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	2,816,138
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 11.36
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	6 years 8 months 16 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	959,167
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares	$ 7.01
Share-based Compensation Arrangement by Share-based Payment Award, Options and Non-Option Equity Instruments, Outstanding [Roll Forward]
Stock Options, Outstanding at December 31, 2011	2,168,668
Stock Options Exercised	(31,369)
Stock Options Forfeited	(74,863)
Stock Options Expired	(89,412)
Stock Options, Outstanding at September 30, 2012	2,932,191	2,168,668
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price \| $ / shares	$ 15.40
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price \| $ / shares	5.54
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price \| $ / shares	$ 4.80
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	2,231,869
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price \| $ / shares	$ 12.14
Options, Vested, weighted Average Remaining Contractual Term	6 years 4 months 24 days

Shareholders' Equity Total compensation cost related to nonvested awards (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2012	Dec. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
weighted average estimated fair value of restricted stock	$ 5.77	$ 6.53
Restricted Stock [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Unrecognized compensation cost		$ 335,600
Excepted weighted-average period in years of compensation cost to be recognized		4 months 17 days
Warrant [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Unrecognized compensation cost		$ 55,600
Excepted weighted-average period in years of compensation cost to be recognized		1 year 6 months 15 days
Stock Option [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Unrecognized compensation cost		$ 2,422,200
Excepted weighted-average period in years of compensation cost to be recognized		3 years 6 months 4 days

Shareholders' Equity Equity Issuances (Details) - USD ($)			2 Months Ended	3 Months Ended	12 Months Ended
	May 03, 2013	Sep. 30, 2012	Feb. 28, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Oct. 31, 2013	Jun. 30, 2013	May 01, 2013	Sep. 30, 2011	Sep. 28, 2011	Nov. 19, 2010
Class of Stock [Line Items]
Warrant inducements					40,407	41,969
Common Stock, Shares, Issued				27,196,537	27,196,537	16,375,365
Proceeds from issuance of common stock					$ 58,736,166	$ 16,428,827
Sale of Stock, Price Per Share								$ 5.60				$ 0.945
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Committment Value Under Purchase Agreement											$ 20,000,000
Term Of Agreement In Months											24
Discount Applied To Weighted Average Price											5.00%
Shares, Issued										99,010
Private Placement [Member]
Class of Stock [Line Items]
Warrant inducements		161,290
Investment Warrants, Exercise Price		$ 6.00
Aegis Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Units offered							5,000,000		2,000,000
Common Stock, Shares, Issued							750,000		300,000
Sale of Stock, Price Per Share							$ 7.000		$ 5
Proceeds from Issuance of Common Stock Gross	$ 11,500,000			$ 40,300,000
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Common Stock, Shares, Issued			1,600,000
Proceeds from issuance of common stock			$ 11,100,000
Purchase Commitment, Remaining Minimum Amount Committed				$ 5,600,000	$ 5,600,000

Shareholders' Equity Warrants (Details) - USD ($)	12 Months Ended
Shareholders' Equity Warrants (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price, Warrants Exercised	$ 5.38
Warrants Issued During Period, Value	$ 149,900	$ 172,200
Warrant inducements	40,407	41,969
Warrant holder A [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	600,000
Warrant Inducement Per Share	$ 0.30
Proceeds from Issuance of Warrants	$ 3,000,000
Minimum [Member] \| Warrant holder A [Member]
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price, Warrants Exercised	$ 5.10
Maximum [Member] \| Warrant holder A [Member]
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price, Warrants Exercised	$ 7.40

Shareholders' Equity Equity Plan (Details) - USD ($)	12 Months Ended
Shareholders' Equity Equity Plan (Details) - USD ($)	Dec. 31, 2013	Oct. 31, 2013	Dec. 31, 2012	Oct. 10, 2012	Oct. 14, 2011	Jan. 18, 2011	Jun. 02, 2010	Oct. 29, 2009	May 09, 2009
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Shares Authorized	500,000,000		500,000,000
Employee Stock Option [Member] \| 2009 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Shares Authorized		2,600,000		450,000	2,375,000	1,775,000	1,375,000	975,000	380,000
Employee Stock Option [Member] \| Non US Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Shares Authorized				570,000	570,000		870,000	470,000
ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Shares Authorized	500,000
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	15.00%
ESPP annual cap	$ 25,000
percentage of stock closing price	85.00%
percentage of ESPP closing price	85.00%
Shares, Issued	23,052
Shares, Outstanding	476,948

Shareholders' Equity Options (Details) - USD ($) $ / shares in Units, shares in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	30
Net proceeds from exercise of options	$ 150,658	$ 0
Maximum [Member]
Class of Stock [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 5.90
Minimum [Member]
Class of Stock [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	$ 4.00

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 19
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph i
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 18
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Share-Based Compensation (Details)	12 Months Ended
Share-Based Compensation (Details)	Dec. 31, 2013 USD ($)
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 2,422,200
Excepted weighted-average period in years of compensation cost to be recognized	3 years 6 months 4 days
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 55,600
Excepted weighted-average period in years of compensation cost to be recognized	1 year 6 months 15 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 335,600
Excepted weighted-average period in years of compensation cost to be recognized	4 months 17 days

Share-Based Compensation Share-Based Compensation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 6,838,700
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	314,000	$ 195,000
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	822,200	432,900
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	5,702,500	6,084,600
Warrant [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition	$ 129,000	$ 171,600
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	73.00%	76.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	79.00%	83.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	0.32%	0.27%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	1.73%	0.88%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price	$ 3.71	$ 4.10
Stock Options [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price	$ 4.29	$ 3.63
Stock Option [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition	$ 3,375,700	$ 5,408,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	61.00%	73.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	79.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	0.13%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	2.67%	0.00%

Share-Based Compensation Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Stock Option [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	61.00%	73.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	79.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	0.13%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	2.67%	0.00%
Warrant [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum	73.00%	76.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum	79.00%	83.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum	0.32%	0.27%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum	1.73%	0.88%
Minimum [Member] \| Stock Option [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Minimum	1 year	2 years
Minimum [Member] \| Warrant [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Minimum	2 years	2 years
Maximum [Member] \| Stock Option [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Minimum	10 years	10 years
Maximum [Member] \| Warrant [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Minimum	5 years	5 years

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Income Tax Examination [Line Items]
Current Federal Tax Expense (Benefit)	$ 476.9	$ 0.0
Current State and Local Tax Expense (Benefit)	$ 303.2	(175.5)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	34.00%
Operating Loss Carryforwards	$ 110,600,000	77,100,000
Current Income Tax Expense (Benefit)	780.1	(175.5)
Income Tax Reconciliation, Income Tax Expense (Benefit), at Federal Statutory Income Tax Rate	(13,159,800)	(12,334,100)
Income Tax Reconciliation, State and Local Income Taxes	(3,430,900)	(2,154,100)
Permanent non deductible expenses for U.S. taxes	(1,798,200)	(2,781,400)
Restatement of Prior Year Income, Net of Tax	(91,400)	321,600
Income Tax Reconciliation, Other Adjustments	(3,822,900)	(384,800)
Income Tax Reconciliation, Undistributed Foreign Earnings	0	(1,810,300)
Income Tax Reconciliation, Change in Enacted Tax Rate	(1,094,800)	525,700
Deferred Tax Assets, Valuation Allowance	20,581,700	18,441,900
Unrecognized Tax Benefits Resulting in Net Operating Loss Carryforward	43,334,800	25,727,700
Deferred Tax Assets, Deferred Income	10,500	23,100
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities	13,600	15,200
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost	7,971,900	5,466,700
Deferred Tax Assets, Goodwill and Intangible Assets	704,600	287,300
Deferred Tax Assets, Other	0	(348,700)
Deferred Tax Assets, Charitable Contribution Carryforwards	414,900	391,800
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts	304,300	239,700
Deferred Tax Assets, Capital Loss Carryforwards	7,036,800	6,644,500
Deferred Tax Assets, Net	59,791,400	39,144,700
Deferred Tax Liabilities Accumulated depreciation	64,800	0
Deferred Tax Liabilities, Goodwill and Intangible Assets, Intangible Assets	(4,379,200)	(3,599,100)
Deferred Income Tax Liabilities	(4,444,000)	(3,599,100)
Deferred Tax Assets (Liabilities), Net	55,347,400	35,545,600
Valuation Allowances and Reserves, Balance	(59,726,600)	(39,144,700)
Deferred Tax Liabilities	$ 4,379,200	$ 3,599,100

Income Taxes Net Operating Loss Carry Forward (Details) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Operating Loss Carryforwards [Line Items]
Provision (benefit) for income taxes	$ 780,104	$ (175,533)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	34.00%

Discontinued Operations (Details)	12 Months Ended
Discontinued Operations (Details)	Dec. 31, 2012 USD ($)
Regenerative Medicine - China segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Revenue	$ 52,300
Disposal Group, Including Discontinued Operation, Costs of Goods Sold	30,600
Disposal Group Including Discontinued Operation Research and Development	103,300
Disposal Group Including Discontinued Operation Selling General and Administrative	497,300
Disposal Group, Including Discontinued Operation, Operating Expense	6,800
Loss on Exit of Segment	1,138,000
Pharmaceutical Manufacturing - China business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents	$ 8,457,500
CBH Acquisition LLC [Member] \| Equity Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Equity Method Investment, Ownership Percentage	51.00%

Discontinued Operations Company recognized loss on exit (Details) - USD ($)	1 Months Ended	12 Months Ended
	Mar. 31, 2012	Dec. 31, 2012
Regenerative Medicine - China segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	$ 1,138,000
Gain (Loss) on Dispostion of Cash and Cash Equivalents [Member] \| Regenerative Medicine - China segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	195,100
Gain (Loss) on Disposition of Prepaid Expenses and Other Current Assets [Member] \| Regenerative Medicine - China segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	14,900
Gain (Loss) on Disposition of Property, Plant and Equipment, Net [Member] \| Regenerative Medicine - China segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	1,023,700
Gain (Loss) on Disposition of Other Assets [Member] \| Regenerative Medicine - China segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	330,500
Gain (Loss) on Disposition of Accounts Payable [Member] \| Regenerative Medicine - China segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	(177,100)
Gain (Loss) on Disposition of Accrued Liabilities [Member] \| Regenerative Medicine - China segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	(79,200)
Gain (Loss) on Disposition of Accumulated Comprehensive Income [Member] \| Regenerative Medicine - China segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	$ (169,900)
Pharmaceutical Manufacturing - China business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment		$ 3,416,400

Discontinued Operations The operating results of the Regenerative Medicine – China business (Details) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Operating Income (Loss)	$ 0	$ (17,955,344)
Regenerative Medicine - China segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Revenue		52,300
Disposal Group, Including Discontinued Operation, Costs of Goods Sold		(30,600)
Disposal Group Including Discontinued Operation Research and Development		(103,300)
Disposal Group Including Discontinued Operation Selling General and Administrative		(497,300)
Disposal Group, Including Discontinued Operation, Operating Expense		(6,800)
Loss on Exit of Segment		1,138,000
Disposal Group, Including Discontinued Operation, Operating Income (Loss)		$ (1,723,700)

- Definition

Amount of income (loss) from a disposal group, net of income tax, reported as a separate component of income before extraordinary items after deduction or consideration of the amount allocable to noncontrolling interests. Includes, net of tax, income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.

+ References + Details

Discontinued Operations The summary of assets and liabilities related to Regenerative Medicine - China business (Details)	Dec. 31, 2012 USD ($)
Assets:
Assets of Disposal Group, Including Discontinued Operation	$ 23,800,300

Discontinued Operations The operating results of pharmaceutical manufacturing - China business (Details)	12 Months Ended
	Dec. 31, 2012 USD ($)
Pharmaceutical Manufacturing - China business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on exit of segment	$ (3,416,400)

Discontinued Operations The summary of the assets and liabilities related to Pharmaceutical Manufacturing- China discontinued operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2013	Nov. 13, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Noncontrolling interests	$ (356,970)	$ (516,040)
Cash and cash equivalents	13,737,452	$ 46,133,759
Total assets	23,800,300
Pharmaceutical Manufacturing - China business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Available-for-sale Securities, Fair Value Disclosure	13,397,900
Noncontrolling interests	6,015,000
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	4,387,400
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents	8,457,500
Cash and cash equivalents			$ 12,300,000
Restricted cash	2,918,100
Accounts receivable, net	6,130,200
Inventory	15,077,700
Prepaid expenses and other current assets	957,800
Property, plant and equipment, net	38,102,000
Other assets	5,946,300
Accounts Payable	(9,604,800)
Accrued liabilities	(2,008,800)
Bank loans	(15,133,500)
Notes payable	(6,599,300)
Unearned revenue	(9,166,800)
Amount due related parties	(7,859,700)
Total Liabilities	27,216,700
Loss on exit of segment	$ (3,416,400)
Treasury Stock, Shares			104,000
Stock Option Cancelled			117,000
Warrants Cancelled			64,000

Related Party Transactions (Details) - Equity Purchase Agreement [Member]	Dec. 31, 2012	Jun. 18, 2012
CBH Acquisition LLC [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage	51.00%
EET and Fullbright [Member]
Related Party Transaction [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent		49.00%

Commitments and Contingencies (Details) - USD ($)	1 Months Ended	12 Months Ended
Commitments and Contingencies (Details) - USD ($)	Aug. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Commitments and Contingencies [Abstract]
Base Monthly Rent Expense of Executive Offices	$ 27,000
Base Monthly Rent Expense of Subleases	$ 7,500
Operating Leases, Future Minimum Payments Due [Abstract]
2013		$ 1,004,000
2014		829,900
2015		671,800
2016		383,400
Thereafter		5,900
Total minimum lease payments		2,895,000
Operating Leases, Rent Expense		$ 1,100,000	$ 1,500,000

Subsequent Events (Details)	2 Months Ended	3 Months Ended	12 Months Ended
Subsequent Events (Details)	Feb. 28, 2013 USD ($) shares	Mar. 31, 2014 USD ($)	Dec. 31, 2013 USD ($) shares	Dec. 31, 2012 USD ($) shares	Mar. 11, 2014 USD ($)	Mar. 07, 2014 $ / shares $ / warrant shares
Subsequent Event [Line Items]
Common Stock, Shares, Issued \| shares			27,196,537	16,375,365
Proceeds from issuance of common stock			$ 58,736,166	$ 16,428,827
Net proceeds from exercise of warrants			$ 3,028,241	6,604,418
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number \| shares			4,780,658
Net proceeds from exercise of options			$ 150,658	$ 0
Aspire Capital Purchase Agreement [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued \| shares	1,600,000
Proceeds from issuance of common stock	$ 11,100,000
Aspire Capital Purchase Agreement [Member] \| Issuance of Equity [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued \| shares						800,000
Proceeds from issuance of common stock		$ 5,600,000
Committment Value Under Purchase Agreement					$ 30,000,000
Term Of Agreement In Months					0
Stock Option [Member] \| Stock Options [Member]
Subsequent Event [Line Items]
Net proceeds from exercise of options		0
Underwriting Offering [Member] \| Warrant [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Additional Number of Securities Called by Warrants or Rights \| shares						250,000
Exercise Price of Warrant Exercise \| $ / warrant						5.10
Net proceeds from exercise of warrants		$ 1,300,000
Stock Options [Member] \| Stock Options [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number \| shares						4,800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price \| $ / shares						$ 6.20